1323:
evaluated in Inter-B-NHL Ritux 2010, a global multicenter, open-label, randomized 1:1 trial of participants six months in age or older with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or B-cell acute leukemia. Advanced stage was defined as stage III with elevated lactose dehydrogenase level (lactose dehydrogenase greater than twice the institutional upper limit of normal values) or stage IV B-cell non-Hodgkin's lymphoma or B-cell acute leukemia. Participants were randomized to
Lymphome Malin B chemotherapy that consisted of corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide, and triple drug (methotrexate/cytarabine/corticosteroid) intrathecal therapy alone or in combination with rituximab or non-US licensed rituximab, administered as six infusions of rituximab IV at a dose of 375 mg/m2 as per the Lymphome Malin B scheme.
549:
526:
854:
arthritis (an inflammatory condition of the joints); two inflammatory conditions of blood vessels known as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA); moderate to severe pemphigus vulgaris, an autoimmune disease characterised by widespread blistering and erosion of the skin and mucous membranes (the linings of internal organs). 'Autoimmune' means that the disease is caused by the immune system (the body's natural defences) attacking the body's own cells.
1135:
1144:
1319:
diseases, in which a person's small blood vessels become inflamed, reducing the amount of blood that can flow through them. This can cause serious problems and damage to organs, most notably the lungs and the kidneys. It also can impact the sinuses and skin. Rituximab was approved by the FDA to treat adults with granulomatosis with polyangiitis and microscopic polyangiitis in 2011.
7431:
3979:
3932:
3883:
2385:
42:
1347:
were approved in the United States, India, the
European Union, Switzerland, Japan, and Australia. The US FDA approved rituximab-abbs (Truxima) in 2018, rituximab-pvvr (Ruxience) in 2019, and rituximab-arrx (Riabni) in 2020. Truxima and Riabni are approximately $ 3600 per 500 mg, wholesale - 10%
4417:
Contreras K, Orozco V, Puche E, González CA, García-Padilla P, Rodríguez MP, et al. (March 2022). "Cost-Effectiveness of
Rituximab (Fixed Schedule vs Tailored Dose) Compared With Azathioprine Maintenance Therapy in Adults With Generalized Antineutrophil Cytoplasm Antibody-Associated Vasculitis
4377:
The pharmaceutical company said Riabni will be marketed at a discount to the reference product of 23.7% below wholesale acquisition cost (WAC), or a WAC of $ 716.80 per 100 mg and $ 3584 per 500 mg single-dose vial. These costs are 15.2% less than the WAC for the biosimilar rituximab
Truxima, Amgen
1318:
In
September 2019, the US FDA approved rituximab injection to treat granulomatosis with polyangiitis and microscopic polyangiitis in children two years of age and older in combination with glucocorticoids (steroid hormones). It is the first approved treatment for children with these rare vasculitis
698:
The most common side effects with intravenous infusions are reactions related to the infusion (such as fever, chills and shivering) while most common serious side effects are infusion reactions, infections and heart-related problems. Similar side effects are seen when it is injected under the skin,
1170:
Rituximab is relatively ineffective in elimination of cells with low CD20 cell-surface levels. It tends to stick to one side of B cells, where CD20 is, forming a cap and drawing proteins over to that side. The presence of the cap changes the effectiveness of natural killer (NK) cells in destroying
1322:
In
December 2021, the US FDA approved rituximab in combination with chemotherapy for children aged 6 months to 18 years with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia. Efficacy was
853:
In the
European Union, rituximab is indicated for the treatment of follicular lymphoma and diffuse large B cell non-Hodgkin's lymphoma (two types of non-Hodgkin's lymphoma, a blood cancer); chronic lymphocytic leukemia (CLL, another blood cancer affecting white blood cells); severe rheumatoid
1314:
In June 2017, the US FDA granted regular approval to the combination of rituximab and hyaluronidase human (brand name
Rituxan Hycela) for adults with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. The combination is not indicated for the treatment of
1402:
and rituximab treatment had higher risk of severe COVID-19. In persons previously treated with rituximab for multiple sclerosis, 9 of 10 patients who delayed re-dosing until B cell counts passed 40/μL developed protective levels of antibodies after vaccination with the
1138:
Rituximab mechanisms of action; the three major independent mechanisms are (1) antibody dependent cellular cytotoxicity (ADCC), (2) complement mediated cytotoxicity (CMC), and (3) apoptosis; subset panel illustrates a schematic view of CD20 structure and
3387:
4679:
Fluge Ø, Rekeland IG, Lien K, Thürmer H, Borchgrevink PC, Schäfer C, et al. (May 2019). "B-Lymphocyte
Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial".
3583:
Borsky M, Hrabcakova V, Novotna J, Brychtova Y, Doubek M, Panovska A, et al. (December 2021). "Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion".
934:
therapy. In the
European Union, the license is slightly more restrictive: it is licensed for use in combination with methotrexate in patients with severe active RA who have had an inadequate response to one or more anti-TNF therapy.
3731:
2173:
4304:
2370:
2162:"FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab)"
1781:
4221:
1171:
these B cells. When an NK cell latched onto the cap, it had an 80% success rate at killing the cell. In contrast, when the B cell lacked this asymmetric protein cluster, it was killed only 40% of the time.
4453:
Romero G, Ticchioni M, Cohen M, Rosenthal-Allieri MA, Mondot L, Lebrun Frenay C (March 2016). "Neuromyelitis optica: Contribution of therapeutic responses markers monitoring in patients given rituximab".
2264:
3957:"FDA D.I.S.C.O. Burst Edition: FDA approvals of Rituxan (rituximab) plus chemotherapy for pediatric cancer indications, and Keytruda (pembrolizumab) for adjuvant treatment of Stage IIB or IIC melanoma"
3131:
Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al. (July 2015). "International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease".
4774:
Bonnan M, Ferrari S, Bertandeau E, Demasles S, Krim E, Miquel M, et al. (2014). "Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials".
3394:
1231:
Rituximab also induces a release of some chronic lymphocytic leukemia cells from immune niches, which might make them more sensitive to chemotherapy used in combination with an anti-CD20 antibody.
5013:
3812:
283:
3835:
2918:
Shanafelt TD, Madueme HL, Wolf RC, Tefferi A (November 2003). "Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome".
2286:
1419:(ME/CFS) symptoms. While initial trials using Rituximab were promising, a phase 3 trial published in 2019 did not find an association between Rituximab treatment and improvements in ME/CFS.
3266:
Molloy ES, Calabrese LH (September 2012). "Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies".
3956:
3411:
Seyfizadeh N, Seyfizadeh N, Hasenkamp J, Huerta-Yepez S (January 2016). "A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections".
3743:
1471:). This strategy for enhancing a monoclonal antibody's ability to induce ADCC takes advantage of the fact that the displayed Fc glycan controls the antibody's affinity for Fc receptors.
2161:
7476:
4723:
Seton KA, Espejo-Oltra JA, Giménez-Orenga K, Haagmans R, Ramadan DJ, Mehlsen J, et al. (European ME Research Group for Early Career Researchers (Young EMERG)) (January 2024).
3860:
1669:
238:
3909:
619:
1235:
The combined effect results in the elimination of B cells (including the cancerous ones) from the body, allowing a new population of healthy B cells to develop from lymphoid
4334:
2501:
1887:
1573:
1504:
1416:
1340:, a class of drugs that are only available through specialty distributors in the US. Because wholesalers discounts and rebates no longer apply, hospitals would pay more.
955:
4300:
6444:
5006:
2362:
930:
for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more anti-
4364:
1771:
4209:
1352:
7456:
3035:
2260:
124:
4809:
2402:
Saini KS, Azim HA, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, et al. (August 2011). "Rituximab in Hodgkin lymphoma: is the target always a hit?".
4999:
1147:
Rituximab binding to CD20. The CD20 proteins are sticking out of the cell membrane, and rituximab, the Y-shaped antibody, is binding to the CD20 proteins.
4725:"Advancing Research and Treatment: An Overview of Clinical Trials in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Future Perspectives"
3827:
1085:
963:
707:
4575:"Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry"
1200:
Preferential elimination of malignant B cells with high CD20 levels and high BCR signaling propensity, especially in chronic lymphocytic leukemia (CLL).
7461:
56:
6853:
1468:
1183:
1307:
Originally available for intravenous injection (e.g. over 2.5 hrs), in 2016, it gained EU approval in a formulation for subcutaneous injection for
6005:
5648:
1394:
A major concern with continuous rituximab treatment is the difficulty to induce a proper vaccine response. This was brought into focus during the
4277:
2693:
3492:"Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity"
1755:
4407:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1947:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
7451:
7385:
7054:
2237:
The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023)
1301:
740:
1404:
879:
699:
with the exception of reactions around the injections site (pain, swelling and rash), which occur more frequently with the skin injections.
7274:
6437:
5141:
2870:
966:(PML) infection, which is usually fatal; however, only a very small number of cases have been recorded occurring in autoimmune diseases.
1934:
1637:
1605:
982:
978:
672:
2215:
1659:
6911:
6838:
6743:
6119:
837:
in combination with chemotherapy for children (≥ 6 months to < 18 years) with previously untreated, advanced stage, CD20-positive
6768:
2745:
2209:
1187:
4624:"Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab"
2067:
Singer O, McCune WJ (May 2017). "Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis".
1415:
In 2009, a patient receiving methotrexate-induced B-cell depletion for cancer treatment, experienced a transient remittal of their
5539:
5065:
3808:
990:
822:
668:
4326:
2493:
1879:
1811:
1565:
1533:
1496:
6430:
1014:
268:
156:
4008:
1315:
non-malignant conditions. The combination was approved based on clinical studies SABRINA/NCT01200758 and MabEase/NCT01649856.
6753:
4489:
Kriston L, Härter M, Hölzel L (March 2009). "Challenges in reporting meta-analyses of diagnostic accuracy studies". Letters.
1179:
4184:
1702:
1367:, for NHL, CLL, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis and pemphigus vulgaris.
2002:
6858:
4839:
4243:
3451:"Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels"
2615:
McGinley MP, Moss BP, Cohen JA (January 2017). "Safety of monoclonal antibodies for the treatment of multiple sclerosis".
1286:
1038:
891:
838:
7421:
4356:
3039:
6717:
5885:
4249:
4215:
3962:
3915:
3866:
3737:
3692:"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma"
2751:
2167:
2024:
Tandan R, Hehir MK, Waheed W, Howard DB (August 2017). "Rituximab treatment of myasthenia gravis: A systematic review".
1270:
1123:
951:
915:
875:
803:
660:
445:
2658:
He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H (December 2013). "Rituximab for relapsing-remitting multiple sclerosis".
1391:
infection, suggesting the drug in combination with lymphoma may have weakened the body's immune response to the virus.
7402:
5042:
4526:"Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response"
3176:"Persistence of Autoreactive IgA-Secreting B Cells Despite Multiple Immunosuppressive Medications Including Rituximab"
970:
505:
6066:
2822:"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura"
1360:
175:
1005:—with very encouraging results of approximately 85% rapid recovery in pemphigus, according to a 2006 study), type 1
6496:
6191:
6040:
5789:
5291:
711:
3660:
6961:
5516:
5382:
5095:
4813:
4132:"Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody"
2232:
1929:
1632:
1600:
1356:
1068:
1030:
7471:
5526:
5052:
1167:
influx across plasma membranes, maintaining intracellular Ca concentration and allowing activation of B cells.
1156:
863:
826:
4378:
said. The company added that Riabni's average sales price will be 16.7% below the current average for Rituxan.
1375:
Tailored-dose rituximab is more cost-effective than fixed-dose. It is both more effective and less expensive.
3910:"FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels"
2523:
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. (June 2004).
1439:
The efficacy and success of rituximab has led to some other anti-CD20 monoclonal antibodies being developed:
7390:
7357:
7298:
7249:
7164:
6788:
5022:
3352:
Burton C, Kaczmarski R, Jan-Mohamed R (June 2003). "Interstitial pneumonitis related to rituximab therapy".
1034:
783:
212:
684:
544:
7328:
7318:
7288:
7079:
7024:
6951:
6941:
6818:
5894:
5377:
5106:
3303:"Peripheral B Cell Deficiency and Predisposition to Viral Infections: The Paradigm of Immune Deficiencies"
756:
494:
3690:
Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. (September 1997).
3036:"Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy"
1957:
1725:"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)"
7466:
7303:
7292:
7254:
7144:
7129:
7059:
7039:
7034:
6813:
6567:
5452:
5392:
5362:
5265:
5101:
4991:
974:
790:
4965:
4273:
2697:
7154:
7014:
6783:
6748:
5307:
5202:
5039:
1752:
1724:
1274:
1073:
1058:
1042:
1026:
911:
809:
797:
692:
664:
656:
361:
219:
119:
rituximab-abbs, rituximab-pvvr, rituximab-arrx, Blitzima Riabni, Rixathon, Riximyo, Ruxience, Truxima
7269:
7239:
7234:
7219:
7049:
6896:
6848:
6808:
6453:
6160:
5427:
5417:
5237:
2820:
Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, et al. (April 2005).
1804:"Mabthera 100 mg Concentrate for Solution for Infusion - Summary of Product Characteristics (SmPC)"
1308:
1294:
1290:
1282:
1077:
1010:
994:
887:
725:
688:
648:
644:
521:
389:
231:
66:
49:
6507:
4980:
2112:"EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts"
1837:"Mabthera 1400 mg Solution for Subcutaneous Injection - Summary of Product Characteristics (SmPC)"
1134:
6991:
6542:
6502:
5815:
5457:
5447:
5432:
5352:
4705:
4661:
4604:
4555:
3156:
2851:
2719:
2640:
2092:
2049:
1399:
947:
902:
to treat previously untreated and previously treated CD20-positive chronic lymphocytic leukemia.
832:
676:
186:
4524:
Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. (July 2008).
4057:"Chimeric anti-CD20 antibody, rituxan, for use in the treatment of chronic lymphocytic leukemia"
3757:
Scott SD (1998). "Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma".
3490:
Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC, et al. (June 2013).
3449:
Pavlasova G, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J, et al. (September 2018).
2893:
1018:
4914:"Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review"
3092:"Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome"
2994:
Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. (November 2008).
2439:"Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management"
2287:"FDA Approves Genentech's Rituxan (rituximab) in Children With Two Rare Blood Vessel Disorders"
6878:
6697:
5492:
4943:
4894:
4791:
4756:
4697:
4653:
4596:
4547:
4506:
4471:
4435:
4113:
3774:
3713:
3642:
3601:
3562:
3513:
3472:
3428:
3369:
3334:
3283:
3248:
3197:
3148:
3113:
3017:
2976:
2935:
2843:
2802:
2671:
2632:
2597:
2546:
2468:
2419:
2341:
2205:
2143:
2084:
2041:
1464:
1395:
1119:
1045:. There is some evidence that it is ineffective in treating IgA-mediated autoimmune diseases.
1022:
1006:
939:
752:
680:
308:
295:
104:
71:
4390:
1924:
1627:
1595:
1262:
under the name IDEC-C2B8. The US patent for the drug was issued in 1998 and expired in 2015.
5332:
5174:
5169:
4933:
4925:
4912:
Maverakis E, Kim K, Shimoda M, Gershwin ME, Patel F, Wilken R, et al. (February 2015).
4884:
4874:
4783:
4746:
4736:
4689:
4643:
4635:
4586:
4537:
4502:
4498:
4463:
4427:
4103:
4095:
3766:
3703:
3632:
3593:
3552:
3544:
3503:
3462:
3420:
3361:
3324:
3314:
3275:
3238:
3228:
3187:
3140:
3103:
3070:
3007:
2966:
2927:
2885:
2833:
2792:
2663:
2624:
2587:
2577:
2536:
2458:
2450:
2411:
2331:
2321:
2240:
2199:
2133:
2123:
2076:
2033:
1388:
899:
842:
561:
398:
343:
4210:"FDA approves first biosimilar for treatment of adult patients with non-Hodgkin's lymphoma"
454:
7435:
3861:"FDA approves rituximab plus hyaluronidase combination for Treatment of FL, DLBCL and CLL"
2525:"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis"
1759:
1218:
846:
351:
3770:
3217:"Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas"
2996:"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients"
2757:
4751:
4724:
4084:"Rituximab: how approval history is reflected by a corresponding patent filing strategy"
548:
525:
7396:
7362:
7029:
6269:
6167:
6115:
5713:
5026:
4938:
4913:
4648:
4639:
4623:
4157:
4108:
4083:
3557:
3532:
3329:
3243:
2592:
2463:
2438:
2336:
2138:
1337:
1266:
1247:
1246:
170–173 and 182–185 on CD20, which are physically close to each other as a result of a
1063:
986:
722:
4889:
4787:
2889:
7445:
7244:
7099:
6652:
6487:
6326:
6216:
6178:
6155:
6087:
6082:
6072:
5848:
5844:
5832:
5639:
5422:
5387:
5207:
5187:
4665:
4608:
3983:
3936:
3887:
3424:
2389:
1836:
1803:
1776:
1664:
883:
813:
768:
537:
321:
148:
4709:
4622:
Tolf A, Wiberg A, Müller M, Nazir FH, Pavlovic I, Laurén I, et al. (May 2022).
4559:
4000:
3160:
3012:
2995:
2855:
2644:
2454:
2096:
2053:
1359:
adopted a positive opinion, recommending the granting of marketing authorization to
7259:
7224:
7209:
7204:
7199:
7194:
7169:
7124:
7119:
7114:
7109:
7094:
6981:
6956:
6936:
6798:
6763:
6702:
6682:
6492:
6477:
6422:
6366:
6351:
6321:
6301:
6183:
6131:
6092:
5980:
5959:
5866:
5828:
5729:
5704:
5700:
5584:
5549:
5502:
5487:
5442:
5317:
5287:
5212:
5030:
4131:
4056:
4030:
2667:
2261:"FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia"
1456:
1278:
927:
923:
886:
human, sold under the brand names MabThera SC and Rituxan Hycela, is used to treat
251:
246:
3597:
3174:
He Y, Shimoda M, Ono Y, Villalobos IB, Mitra A, Konia T, et al. (June 2015).
2628:
1343:
Patents on rituximab have expired in the European Union and in the United States.
4467:
3637:
3620:
3508:
3491:
3215:
Kyriakidis I, Mantadakis E, Stiakaki E, Groll AH, Tragiannidis A (October 2022).
3192:
3175:
2080:
1998:
1694:
134:
7367:
7341:
7336:
7308:
7284:
7279:
7214:
7189:
7179:
7149:
7139:
7104:
7089:
7074:
7064:
7044:
7019:
7004:
6976:
6926:
6921:
6916:
6901:
6891:
6868:
6863:
6833:
6778:
6722:
6712:
6687:
6677:
6672:
6667:
6642:
6617:
6607:
6602:
6597:
6587:
6572:
6557:
6552:
6537:
6532:
6522:
6517:
6512:
6482:
6396:
6376:
6371:
6361:
6341:
6316:
6311:
6294:
6242:
6232:
6227:
6222:
6124:
6051:
6021:
6016:
6011:
5995:
5985:
5965:
5840:
5836:
5824:
5820:
5749:
5653:
5599:
5594:
5559:
5497:
5482:
5472:
5467:
5462:
5437:
5402:
5357:
5337:
5327:
5282:
5247:
5227:
5183:
5146:
5134:
5129:
5091:
5075:
3548:
3365:
2955:"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin"
1460:
1443:
1428:
1384:
1259:
1207:
and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen).
1160:
1143:
1095:
895:
779:
703:
142:
4929:
4835:
4431:
3533:"B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience"
2869:
Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB (2007).
2797:
2780:
2582:
2565:
2415:
7313:
7264:
7229:
7159:
7134:
7084:
7069:
7009:
6999:
6971:
6946:
6886:
6828:
6823:
6758:
6738:
6692:
6662:
6657:
6647:
6637:
6632:
6622:
6612:
6582:
6577:
6547:
6527:
6411:
6406:
6381:
6346:
6331:
6306:
6289:
6279:
6237:
6208:
6173:
6139:
6056:
6046:
6026:
5990:
5975:
5970:
5940:
5874:
5870:
5852:
5800:
5779:
5739:
5734:
5673:
5604:
5579:
5554:
5477:
5412:
5372:
5367:
5347:
5342:
5322:
5312:
5302:
5217:
5197:
5179:
5087:
4863:"Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?"
4591:
4574:
3467:
3450:
3319:
3302:
2781:"Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story"
1449:
1344:
1243:
1194:
1113:
1002:
919:
818:
600:
429:
226:
114:
3708:
3691:
3063:"Immunomodulators and Rituximab in the Management of Autoimmune Pancreatitis"
2128:
2111:
7184:
7174:
6931:
6906:
6843:
6803:
6793:
6773:
6707:
6627:
6592:
6562:
6401:
6391:
6386:
6356:
6336:
6284:
6274:
6262:
6257:
6203:
6198:
6144:
6077:
5950:
5945:
5930:
5925:
5920:
5910:
5905:
5900:
5805:
5795:
5774:
5769:
5764:
5759:
5754:
5744:
5724:
5688:
5683:
5678:
5668:
5663:
5630:
5625:
5620:
5589:
5569:
5564:
5407:
5397:
5070:
4542:
4525:
3233:
3216:
1236:
1225:
998:
943:
931:
878:, and nodular lymphocyte predominant Hodgkin's lymphoma. This also includes
748:
715:
374:
128:
4947:
4898:
4795:
4760:
4701:
4657:
4600:
4551:
4510:
4475:
4439:
4117:
3646:
3605:
3566:
3517:
3476:
3432:
3373:
3338:
3287:
3252:
3201:
3152:
3117:
3108:
3091:
3021:
2980:
2939:
2847:
2806:
2675:
2636:
2601:
2550:
2472:
2423:
2363:"FDA approves rituximab plus chemotherapy for pediatric cancer indications"
2345:
2326:
2309:
2147:
2088:
2045:
3828:"EU approves second indication for subcutaneous form of Roche's rituximab"
3778:
3717:
1387:
infection in a person with lymphoma. Hepatitis E infection is normally an
1155:. CD20 is widely expressed on B cells, from early pre-B cells to later in
778:. It acts by depleting normal as well as pathogenic B cells while sparing
33:
6462:
6151:
5915:
5719:
5658:
5614:
5574:
5544:
5297:
5161:
5157:
5082:
3075:
3062:
2971:
2954:
2746:"FDA Warns of Safety Concern Regarding Rituxan in New Patient Population"
2541:
2524:
1107:
1089:
871:
867:
409:
170:
4741:
4244:"FDA approves Truxima as biosimilar to Rituxan for non-Hodgkin's lympho"
3668:
2245:
969:
Other autoimmune diseases that have been treated with rituximab include
942:, in a range of other autoimmune diseases, and rituximab is widely used
418:
5255:
4099:
3619:
Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M (September 2006).
3388:"Reports of Bowel Obstruction and Perforation with Rituxan (rituximab)"
2931:
1164:
1053:
Serious adverse events, which can cause death and disability, include:
771:
733:
87:
17:
3279:
3144:
2838:
2821:
2779:
Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P (November 2015).
2037:
1772:"Health product highlights 2021: Annexes of products approved in 2021"
41:
4693:
1204:
959:
775:
767:
Rituximab is a chimeric monoclonal antibody targeted against CD20, a
744:
652:
485:
4301:"Novartis abandons effort for U.S. approval of biosimilar rituximab"
4879:
4862:
3301:
Grammatikos A, Donati M, Johnston SL, Gompels MM (30 August 2021).
962:. The most dangerous, although among the most rare, side effect is
894:, and chronic lymphocytic leukemia. It is used in combination with
663:(in children and adults, but not recommended in elderly patients),
474:
6135:
5861:
5695:
5644:
5124:
3090:
Pranzatelli MR, Tate ED, Travelstead AL, Longee D (January 2005).
1163:. Although the function of CD20 is unknown, it may play a role in
1142:
1133:
79:
75:
4573:
Spelman T, Forsberg L, McKay K, Glaser A, Hillert J (June 2022).
3982:
This article incorporates text from this source, which is in the
3935:
This article incorporates text from this source, which is in the
3886:
This article incorporates text from this source, which is in the
2494:"Rituxan Hycela- rituximab and hyaluronidase injection, solution"
2388:
This article incorporates text from this source, which is in the
1289:
and many other B-cell lymphomas. In 2010, it was approved by the
6250:
6036:
5534:
5260:
5242:
5232:
5192:
5060:
2694:"Popular Cancer Drug Linked to Often Fatal 'Brain Eating' Virus"
1383:
Rituximab has been reported as a possible cofactor in a chronic
1211:
1152:
729:
465:
330:
302:
92:
6426:
4995:
3809:"Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy"
315:
165:
2953:
Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (October 2006).
2871:"Long-term responses seen with rituximab in patients with ITP"
2696:. Northwestern University News and Information. Archived from
1732:
2443:
Hematology. American Society of Hematology. Education Program
2310:"Shifting Focus in the Therapeutics of Immunobullous Disease"
739:
Rituximab was approved for medical use in 1997. It is on the
1348:
less than Rituxan. While Ruxience is 24% less than Rituxan.
1106:
Immune toxicity, with depletion of B cells in 70% to 80% of
510:
732:, which is primarily found on the surface of immune system
277:
197:
2110:
Dojcinov SD, Fend F, Quintanilla-Martinez L (March 2018).
938:
There is some evidence for efficacy, but not necessarily
379:
Uncertain: may undergo phagocytosis and catabolism in RES
4966:
Non-Hodgkin's lymphoma: rituximab subcutaneous injection
736:. When it binds to this protein it triggers cell death.
369:
30 to 400 hours (varies by dose and length of treatment)
290:
2720:"Popular Cancer Drug Linked To Often Fatal Brain Virus"
2488:
2486:
2484:
2482:
2204:. Springer Science & Business Media. pp. 1–4.
1302:
World Health Organization's List of Essential Medicines
741:
World Health Organization's List of Essential Medicines
626:
4327:"Teva, Celltrion Maintain Slender Discount to Rituxan"
4276:. Generics and Biosimilars Initiative. 14 April 2017.
922:
rheumatoid disease. In the United States, it has been
7419:
3951:
3949:
3947:
3945:
2566:"Advances in rheumatology: new targeted therapeutics"
2001:. The American Society of Health-System Pharmacists.
1689:
1687:
1293:
for maintenance treatment after initial treatment of
1874:
1872:
1870:
1868:
1866:
1864:
1862:
1860:
1858:
1528:
1526:
1524:
1522:
7350:
7327:
6990:
6877:
6731:
6470:
6461:
6107:
5884:
5525:
5515:
5275:
5156:
5116:
5051:
5038:
1831:
1829:
1491:
1489:
1487:
1485:
1446:, humanized (90%-95% human) B cell-depleting agent.
845:(BL), Burkitt-like lymphoma (BLL), or mature acute
599:
560:
555:
536:
504:
484:
464:
444:
428:
408:
388:
383:
373:
360:
350:
342:
267:
262:
237:
225:
211:
185:
155:
141:
123:
113:
103:
98:
86:
65:
55:
48:
3904:
3902:
3900:
3898:
3896:
1753:Rituximab (rch) (CAS registry number: 174722-31-7)
1560:
1558:
1556:
1554:
1452:(HuMax-CD20) a fully human B cell-depleting agent.
1427:For CNS diseases, rituximab could be administered
1417:myalgic encephalomyelitis/chronic fatigue syndrome
1411:Myalgic encephalomyelitis/chronic fatigue syndrome
718:is safe for the developing fetus or newborn baby.
4185:"Roche Settles With Pfizer Over Rituximab Patent"
2756:(Press release). 18 December 2006. Archived from
1193:Rituximab has a general regulatory effect on the
956:chronic inflammatory demyelinating polyneuropathy
786:, which do not express the CD20 surface antigen.
3393:. Roche Canada. 10 November 2006. Archived from
1919:
1917:
1915:
1913:
1911:
1909:
1907:
1905:
1285:, is superior to CHOP alone in the treatment of
1159:, but it is absent on terminally differentiated
4357:"Amgen Rituximab Biosimilar Gains FDA Approval"
3855:
3853:
3578:
3576:
3444:
3442:
2357:
2355:
1151:The antibody binds to the cell surface protein
882:, a type of NHL. Rituximab in combination with
397:
4001:"Hospitals Furious at Cancer-Drug Price Hikes"
3531:Shaw T, Quan J, Totoritis MC (November 2003).
2201:Drugs Targeting B-Cells in Autoimmune Diseases
2198:Bosch X, Ramos-Casals M, Khamashta MA (2013).
1353:Committee for Medicinal Products for Human Use
7477:World Health Organization essential medicines
6438:
5007:
2289:(Press release). Genentech. 27 September 2019
1660:"Summary Basis of Decision (SBD) for Riximyo"
1534:"Ruxience- rituximab-pvvr injection solution"
1336:In 2014, Genentech reclassified Rituxan as a
8:
3994:
3992:
1497:"Truxima- rituximab-abbs injection solution"
910:Rituximab has been shown to be an effective
702:Severe side effects include reactivation of
174:
32:
2660:The Cochrane Database of Systematic Reviews
2263:(Press release). Biogen. 18 February 2010.
1993:
1991:
1989:
1987:
1985:
1983:
1981:
1979:
1566:"Riabni- rituximab-arrx injection solution"
755:elsewhere except Japan, and co-marketed by
6467:
6445:
6431:
6423:
5522:
5048:
5014:
5000:
4992:
4031:"Recombinant antibodies for human therapy"
3792:Harrison's Principles of Internal Medicine
2308:De A, Ansari A, Sharma N, Sarda A (2017).
2227:
2225:
2193:
2191:
1086:Progressive multifocal leukoencephalopathy
964:progressive multifocal leukoencephalopathy
812:having inadequate response to one or more
708:progressive multifocal leukoencephalopathy
547:
524:
4937:
4888:
4878:
4750:
4740:
4647:
4590:
4541:
4107:
3707:
3636:
3556:
3507:
3466:
3328:
3318:
3242:
3232:
3191:
3107:
3074:
3011:
2970:
2837:
2796:
2591:
2581:
2540:
2462:
2437:Eichenauer DA, Engert A (December 2017).
2335:
2325:
2244:
2137:
2127:
1281:regimens. Rituximab, in combination with
1265:Based on its safety and effectiveness in
714:, and death. It is unclear if use during
453:
4299:Lahiri D, Osterman C (2 November 2018).
3732:"Rituximab Product Approval Information"
1880:"Rituxan- rituximab injection, solution"
1469:antibody-dependent cellular cytotoxicity
1184:antibody-dependent cellular cytotoxicity
7426:
4503:10.7326/0003-4819-150-6-200903170-00025
3413:Critical Reviews in Oncology/Hematology
1481:
1174:The following effects have been found:
520:
417:
147:
4981:"Discovery – Development of Rituximab"
4810:"Genmab.com / HuMax-CD20 (ofatumumab)"
2687:
2685:
695:(injected slowly through an IV line).
538:
31:
4842:from the original on 10 November 2007
4280:from the original on 24 February 2024
4224:from the original on 15 December 2019
3815:from the original on 31 October 2010.
3621:"The epitope recognized by rituximab"
2785:European Journal of Internal Medicine
2239:. Geneva: World Health Organization.
2218:from the original on 5 November 2017.
1937:from the original on 9 September 2021
1640:from the original on 9 September 2021
1608:from the original on 9 September 2021
1431:and this possibility is under study.
493:
133:
7:
7457:Drugs developed by Hoffmann-La Roche
4307:from the original on 3 November 2018
4011:from the original on 20 October 2015
3771:10.1046/j.1523-5394.1998.006003195.x
2373:from the original on 3 December 2021
1962:Union Register of medicinal products
1814:from the original on 21 January 2022
1455:Third-generation anti-CD20s such as
874:, including non-Hodgkin's lymphoma,
250:
4220:(Press release). 28 November 2018.
3354:The New England Journal of Medicine
2959:The New England Journal of Medicine
2529:The New England Journal of Medicine
1705:from the original on 30 August 2019
1269:, rituximab was approved by the US
983:idiopathic thrombocytopenic purpura
979:thrombotic thrombocytopenic purpura
789:In the United States, rituximab is
673:idiopathic thrombocytopenic purpura
473:
4640:10.1001/jamanetworkopen.2022.11497
4367:from the original on 23 April 2021
4337:from the original on 30 March 2024
3920:(Press release). 27 September 2019
3742:. 20 February 2009. Archived from
3061:Hart PA, Chari ST (11 June 2013).
2504:from the original on 27 March 2021
2176:from the original on 28 April 2020
2005:from the original on 27 March 2016
1890:from the original on 4 August 2020
1784:from the original on 25 March 2024
1576:from the original on 25 March 2021
1507:from the original on 25 March 2021
25:
4788:10.2174/1389450115666141029234644
3360:(26): 2690–1, discussion 2690–1.
2367:U.S. Food and Drug Administration
1250:between amino acids 167 and 183.
1188:complement-dependent cytotoxicity
864:cancers of the white blood system
647:medication used to treat certain
7462:Monoclonal antibodies for tumors
7429:
4530:Annals of the Rheumatic Diseases
3977:
3930:
3881:
3838:from the original on 7 June 2016
3537:Annals of the Rheumatic Diseases
3425:10.1016/j.critrevonc.2015.09.001
2570:Arthritis Research & Therapy
2383:
2267:from the original on 9 July 2021
1695:"Rituximab Use During Pregnancy"
1672:from the original on 30 May 2022
1405:Pfizer–BioNTech COVID-19 vaccine
991:granulomatosis with polyangiitis
823:granulomatosis with polyangiitis
669:granulomatosis with polyangiitis
578:
572:
40:
4968:(Report). NICE. September 2014.
4420:Value in Health Regional Issues
3013:10.1001/archneur.65.11.noc80069
2455:10.1182/asheducation-2017.1.324
2069:Current Opinion in Rheumatology
1363:for their rituximab biosimilar
1015:anti-NMDA receptor encephalitis
918:and is now licensed for use in
880:Waldenström's macroglobulinemia
4158:"Methods related to rituximab"
3999:Saporito B (27 October 2014).
2826:American Journal of Hematology
2668:10.1002/14651858.CD009130.pub3
2564:Tak PP, Kalden JR (May 2011).
1463:(Fc) with enhanced binding to
1273:(FDA) in 1997 to treat B-cell
1182:portion of rituximab mediates
706:in those previously infected,
590:
584:
566:
1:
3598:10.1016/j.leukres.2021.106684
2890:10.1016/s1548-5315(11)70061-4
2629:10.1080/14740338.2017.1250881
2617:Expert Opinion on Drug Safety
2314:Indian Journal of Dermatology
1287:diffuse large B-cell lymphoma
1039:Opsoclonus myoclonus syndrome
997:skin disorders (for example,
892:diffuse large B-cell lymphoma
839:diffuse large B-cell lymphoma
7452:Drugs developed by Genentech
4729:Journal of Clinical Medicine
4468:10.1016/j.neurol.2015.12.004
4250:Food and Drug Administration
4216:Food and Drug Administration
3963:Food and Drug Administration
3916:Food and Drug Administration
3867:Food and Drug Administration
3738:Food and Drug Administration
3638:10.1182/blood-2006-04-014639
3509:10.1182/blood-2013-02-482570
3193:10.1001/jamadermatol.2015.59
3133:Arthritis & Rheumatology
2752:Food and Drug Administration
2168:Food and Drug Administration
2081:10.1097/BOR.0000000000000382
1271:Food and Drug Administration
952:systemic lupus erythematosus
946:to treat difficult cases of
926:for use in combination with
916:randomised controlled trials
876:chronic lymphocytic leukemia
804:chronic lymphocytic leukemia
759:and Zenyaku Kogyo in Japan.
743:. Rituxan is co-marketed by
661:chronic lymphocytic leukemia
639:, sold under the brand name
4682:Annals of Internal Medicine
4491:Annals of Internal Medicine
4183:Inserro A (25 March 2019).
3549:10.1136/ard.62.suppl_2.ii55
3366:10.1056/NEJM200306263482619
1435:Other anti-CD20 monoclonals
1258:Rituximab was developed by
971:autoimmune hemolytic anemia
862:Rituximab is used to treat
7493:
5517:Tyrosine kinase inhibitors
4930:10.1016/j.jaut.2014.12.002
4432:10.1016/j.vhri.2021.08.002
4361:The Center For Biosimilars
4274:"Biosimilars of Rituximab"
2798:10.1016/j.ejim.2015.07.021
2583:10.1186/1478-6354-13-S1-S5
2416:10.1016/j.ctrv.2010.11.005
2297:– via Business Wire.
2249:. WHO/MHP/HPS/EML/2023.02.
712:toxic epidermal necrolysis
556:Chemical and physical data
7380:
6962:Mirvetuximab soravtansine
5383:Mirvetuximab soravtansine
4985:National Cancer Institute
4592:10.1177/13524585211026272
4395:European Medicines Agency
3826:Stanton D (31 May 2016).
3468:10.1038/s41375-018-0211-0
3320:10.3389/fimmu.2021.731643
2233:World Health Organization
1930:European Medicines Agency
1633:European Medicines Agency
1601:European Medicines Agency
1357:European Medicines Agency
1069:Cytokine release syndrome
616:
109:Rituxan, Mabthera, others
39:
5527:Receptor tyrosine kinase
5053:Receptor tyrosine kinase
3709:10.1182/blood.V90.6.2188
3268:Arthritis and Rheumatism
2404:Cancer Treatment Reviews
2129:10.3390/pathogens7010028
1758:30 November 2015 at the
827:microscopic polyangiitis
784:hematopoietic stem cells
7358:Depatuxizumab mafodotin
7299:Tucotuzumab celmoleukin
7250:Rovalpituzumab tesirine
7165:Lorvotuzumab mertansine
7055:Clivatuzumab tetraxetan
5117:Others for solid tumors
5023:Targeted cancer therapy
4918:Journal of Autoimmunity
4543:10.1136/ard.2007.077461
3307:Frontiers in Immunology
3234:10.3390/cancers14205022
2920:Mayo Clinic Proceedings
1467:, which increase ADCC (
1459:have a glycoengineered
1210:It elicits shedding of
1035:autoimmune pancreatitis
298: / Schedule D
7319:Vorsetuzumab mafodotin
7275:Tacatuzumab tetraxetan
7080:Denintuzumab mafodotin
7025:Bivatuzumab mertansine
6952:Loncastuximab tesirine
6942:Indatuximab ravtansine
6819:Naptumomab estafenatox
5378:Loncastuximab tesirine
5107:Trastuzumab deruxtecan
4867:Breast Cancer Research
4331:Center for Biosimilars
4189:Center for Biosimilars
3543:(Suppl 2): ii55–ii59.
3109:10.1542/peds.2004-0845
2692:Paul M (20 May 2009).
2327:10.4103/ijd.IJD_199_17
1148:
1140:
1101:Other viral infections
1031:Graves' ophthalmopathy
757:Chugai Pharmaceuticals
691:. It is given by slow
27:Biopharmaceutical drug
7304:Vandortuzumab vedotin
7255:Sacituzumab govitecan
7145:Inotuzumab ozogamicin
7130:Gemtuzumab ozogamicin
7060:Cofetuzumab pelidotin
7040:Cantuzumab ravtansine
7035:Cantuzumab mertansine
6854:Nofetumomab merpentan
6814:Moxetumomab pasudotox
6568:Glembatumumab vedotin
6454:Monoclonal antibodies
5453:Sacituzumab govitecan
5393:Moxetumomab pasudotox
5363:Inotuzumab ozogamicin
5266:Gemtuzumab ozogamicin
5102:Trastuzumab emtansine
5043:monoclonal antibodies
5027:antineoplastic agents
3000:Archives of Neurology
1933:. 17 September 2018.
1398:, where persons with
1275:non-Hodgkin lymphomas
1217:It downregulates the
1146:
1137:
975:pure red cell aplasia
7351:Chimeric + humanized
7155:Lifastuzumab vedotin
7015:Belantamab mafodotin
6784:Ibritumomab tiuxetan
6749:Anatumomab mafenatox
5308:Belantamab mafodotin
4816:on 11 September 2007
4776:Current Drug Targets
4363:. 17 December 2020.
3746:on 10 February 2017.
3076:10.3998/panc.2013.20
2972:10.1056/nejmoa062930
2899:on 29 September 2007
2542:10.1056/NEJMoa032534
2172:. 29 February 2016.
1701:. 16 December 2019.
1260:IDEC Pharmaceuticals
1130:Mechanisms of action
1074:Tumor lysis syndrome
1043:IgG4-related disease
1027:MOG antibody disease
989:, vasculitis (e.g.,
912:rheumatoid arthritis
810:rheumatoid arthritis
798:non-Hodgkin lymphoma
728:against the protein
693:intravenous infusion
689:mucocutaneous ulcers
665:rheumatoid arthritis
657:non-Hodgkin lymphoma
7270:Sofituzumab vedotin
7240:Polatuzumab vedotin
7235:Pinatuzumab vedotin
7220:Oportuzumab monatox
7050:Citatuzumab bogatox
6912:Derlotuximab biotin
6897:Brentuximab vedotin
6849:Taplitumomab paptox
6839:Satumomab pendetide
6809:Nacolomab tafenatox
6744:Altumomab pentetate
6161:Denileukin diftitox
5823:(ALK, ROS1, NTRK),
5428:Polatuzumab vedotin
5418:Oportuzumab monatox
4742:10.3390/jcm13020325
3811:. 29 October 2010.
3796:McGraw Hill Medical
2500:. 3 December 2019.
2369:. 3 December 2021.
1886:. 6 November 2019.
1668:. 23 October 2014.
1327:Society and culture
1309:B-cell CLL/lymphoma
1295:follicular lymphoma
1291:European Commission
1277:resistant to other
1242:Rituximab binds to
1078:acute kidney injury
914:treatment in three
906:Autoimmune diseases
888:follicular lymphoma
831:moderate to severe
726:monoclonal antibody
649:autoimmune diseases
645:monoclonal antibody
643:among others, is a
311:(Prescription only)
286:(Prescription only)
232:Monoclonal antibody
50:Monoclonal antibody
36:
7407:Never to phase III
6769:Capromab pendetide
6543:Enfortumab vedotin
5847:(ROS1, TRK, ALK),
5353:Enfortumab vedotin
4861:Eccles SA (2001).
4579:Multiple Sclerosis
4456:Revue Neurologique
4254:. 28 November 2018
4100:10.4161/mabs.29105
3832:BioPharma-Reporter
2932:10.4065/78.11.1340
2878:Community Oncology
2876:. Correspondence.
2026:Muscle & Nerve
1465:Fc gamma receptors
1400:multiple sclerosis
1361:Reddy Holding GmbH
1351:In July 2024, the
1149:
1141:
948:multiple sclerosis
833:pemphigus vulgaris
685:Epstein–Barr virus
677:pemphigus vulgaris
7417:
7416:
7376:
7375:
6698:Tisotumab vedotin
6420:
6419:
6103:
6102:
5511:
5510:
5493:Tisotumab vedotin
4782:(13): 1205–1214.
4628:JAMA Network Open
4138:. 9 November 1999
4063:. 9 November 1999
3967:. 2 December 2021
3671:on 5 January 2014
3586:Leukemia Research
3502:(23): 4694–4702.
3400:on 27 March 2014.
3280:10.1002/art.34468
3145:10.1002/art.39132
3042:on 22 August 2017
3006:(11): 1443–1448.
2965:(17): 1772–1779.
2926:(11): 1340–1346.
2839:10.1002/ajh.20276
2535:(25): 2572–2581.
2038:10.1002/mus.25597
1810:. 13 March 2021.
1780:. 3 August 2022.
1396:COVID-19 pandemic
1283:CHOP chemotherapy
1120:Bowel obstruction
1059:infusion reaction
1023:Anti-AQP4 disease
1007:diabetes mellitus
681:myasthenia gravis
655:. It is used for
634:
633:
506:CompTox Dashboard
334:
319:
306:
293:
281:
201:
168:
16:(Redirected from
7484:
7434:
7433:
7432:
7425:
7329:Rat/mouse hybrid
6468:
6447:
6440:
6433:
6424:
6134:peptide against
5707:(AXL, ALK, LTK))
5523:
5333:Dinutuximab beta
5049:
5016:
5009:
5002:
4993:
4988:
4969:
4952:
4951:
4941:
4909:
4903:
4902:
4892:
4882:
4858:
4852:
4851:
4849:
4847:
4832:
4826:
4825:
4823:
4821:
4812:. Archived from
4806:
4800:
4799:
4771:
4765:
4764:
4754:
4744:
4720:
4714:
4713:
4694:10.7326/M18-1451
4676:
4670:
4669:
4651:
4619:
4613:
4612:
4594:
4585:(7): 1051–1059.
4570:
4564:
4563:
4545:
4521:
4515:
4514:
4486:
4480:
4479:
4450:
4444:
4443:
4414:
4408:
4406:
4404:
4402:
4387:
4381:
4380:
4374:
4372:
4353:
4347:
4346:
4344:
4342:
4323:
4317:
4316:
4314:
4312:
4296:
4290:
4289:
4287:
4285:
4270:
4264:
4263:
4261:
4259:
4240:
4234:
4233:
4231:
4229:
4206:
4200:
4199:
4197:
4195:
4180:
4174:
4173:
4171:
4169:
4154:
4148:
4147:
4145:
4143:
4128:
4122:
4121:
4111:
4082:Storz U (2014).
4079:
4073:
4072:
4070:
4068:
4053:
4047:
4046:
4044:
4042:
4027:
4021:
4020:
4018:
4016:
3996:
3987:
3981:
3980:
3976:
3974:
3972:
3953:
3940:
3934:
3933:
3929:
3927:
3925:
3906:
3891:
3885:
3884:
3880:
3878:
3876:
3857:
3848:
3847:
3845:
3843:
3823:
3817:
3816:
3805:
3799:
3789:
3783:
3782:
3754:
3748:
3747:
3728:
3722:
3721:
3711:
3702:(6): 2188–2195.
3687:
3681:
3680:
3678:
3676:
3667:. Archived from
3657:
3651:
3650:
3640:
3631:(6): 1975–1978.
3616:
3610:
3609:
3580:
3571:
3570:
3560:
3528:
3522:
3521:
3511:
3487:
3481:
3480:
3470:
3461:(9): 2028–2031.
3446:
3437:
3436:
3408:
3402:
3401:
3399:
3392:
3384:
3378:
3377:
3349:
3343:
3342:
3332:
3322:
3298:
3292:
3291:
3274:(9): 3043–3051.
3263:
3257:
3256:
3246:
3236:
3212:
3206:
3205:
3195:
3180:JAMA Dermatology
3171:
3165:
3164:
3139:(7): 1688–1699.
3128:
3122:
3121:
3111:
3102:(1): e115–e119.
3087:
3081:
3080:
3078:
3058:
3052:
3051:
3049:
3047:
3038:. Archived from
3032:
3026:
3025:
3015:
2991:
2985:
2984:
2974:
2950:
2944:
2943:
2915:
2909:
2908:
2906:
2904:
2898:
2892:. Archived from
2875:
2866:
2860:
2859:
2841:
2817:
2811:
2810:
2800:
2776:
2770:
2769:
2767:
2765:
2742:
2736:
2735:
2733:
2731:
2716:
2710:
2709:
2707:
2705:
2689:
2680:
2679:
2662:(12): CD009130.
2655:
2649:
2648:
2612:
2606:
2605:
2595:
2585:
2561:
2555:
2554:
2544:
2520:
2514:
2513:
2511:
2509:
2490:
2477:
2476:
2466:
2434:
2428:
2427:
2399:
2393:
2387:
2386:
2382:
2380:
2378:
2359:
2350:
2349:
2339:
2329:
2305:
2299:
2298:
2296:
2294:
2283:
2277:
2276:
2274:
2272:
2257:
2251:
2250:
2248:
2229:
2220:
2219:
2195:
2186:
2185:
2183:
2181:
2158:
2152:
2151:
2141:
2131:
2107:
2101:
2100:
2064:
2058:
2057:
2021:
2015:
2014:
2012:
2010:
1995:
1974:
1973:
1971:
1969:
1954:
1948:
1946:
1944:
1942:
1921:
1900:
1899:
1897:
1895:
1876:
1853:
1852:
1850:
1848:
1833:
1824:
1823:
1821:
1819:
1800:
1794:
1793:
1791:
1789:
1768:
1762:
1750:
1744:
1743:
1741:
1739:
1729:nctr-crs.fda.gov
1721:
1715:
1714:
1712:
1710:
1691:
1682:
1681:
1679:
1677:
1656:
1650:
1649:
1647:
1645:
1636:. 15 June 2017.
1624:
1618:
1617:
1615:
1613:
1604:. 13 July 2017.
1592:
1586:
1585:
1583:
1581:
1562:
1549:
1548:
1546:
1544:
1530:
1517:
1516:
1514:
1512:
1493:
1088:(PML) caused by
1011:Sjögren syndrome
900:cyclophosphamide
843:Burkitt lymphoma
630:
629:
622:
611:
609:
592:
586:
580:
574:
568:
551:
540:
529:
528:
514:
512:
497:
477:
457:
421:
401:
365:
332:
329:
324:
317:
314:
304:
301:
292:
289:
279:
276:
254:
199:
196:
178:
167:
164:
151:
137:
44:
37:
35:
21:
7492:
7491:
7487:
7486:
7485:
7483:
7482:
7481:
7472:Specialty drugs
7442:
7441:
7440:
7430:
7428:
7420:
7418:
7413:
7412:
7397:Clinical trials
7372:
7346:
7323:
6986:
6873:
6727:
6457:
6451:
6421:
6416:
6270:Pi3K inhibitors
6168:mTOR inhibitors
6099:
5880:
5851:(VEGFR, FGFR),
5507:
5271:
5152:
5112:
5034:
5020:
4987:. 7 March 2014.
4979:
4976:
4964:
4961:
4959:Further reading
4956:
4955:
4911:
4910:
4906:
4860:
4859:
4855:
4845:
4843:
4834:
4833:
4829:
4819:
4817:
4808:
4807:
4803:
4773:
4772:
4768:
4722:
4721:
4717:
4678:
4677:
4673:
4634:(5): e2211497.
4621:
4620:
4616:
4572:
4571:
4567:
4523:
4522:
4518:
4488:
4487:
4483:
4452:
4451:
4447:
4416:
4415:
4411:
4400:
4398:
4391:"Ituxredi EPAR"
4389:
4388:
4384:
4370:
4368:
4355:
4354:
4350:
4340:
4338:
4325:
4324:
4320:
4310:
4308:
4298:
4297:
4293:
4283:
4281:
4272:
4271:
4267:
4257:
4255:
4242:
4241:
4237:
4227:
4225:
4208:
4207:
4203:
4193:
4191:
4182:
4181:
4177:
4167:
4165:
4156:
4155:
4151:
4141:
4139:
4130:
4129:
4125:
4081:
4080:
4076:
4066:
4064:
4055:
4054:
4050:
4040:
4038:
4029:
4028:
4024:
4014:
4012:
3998:
3997:
3990:
3978:
3970:
3968:
3955:
3954:
3943:
3931:
3923:
3921:
3908:
3907:
3894:
3882:
3874:
3872:
3859:
3858:
3851:
3841:
3839:
3825:
3824:
3820:
3807:
3806:
3802:
3794:, Longo et al.
3790:
3786:
3759:Cancer Practice
3756:
3755:
3751:
3730:
3729:
3725:
3689:
3688:
3684:
3674:
3672:
3665:go.drugbank.com
3659:
3658:
3654:
3618:
3617:
3613:
3582:
3581:
3574:
3530:
3529:
3525:
3489:
3488:
3484:
3448:
3447:
3440:
3410:
3409:
3405:
3397:
3390:
3386:
3385:
3381:
3351:
3350:
3346:
3300:
3299:
3295:
3265:
3264:
3260:
3214:
3213:
3209:
3173:
3172:
3168:
3130:
3129:
3125:
3089:
3088:
3084:
3060:
3059:
3055:
3045:
3043:
3034:
3033:
3029:
2993:
2992:
2988:
2952:
2951:
2947:
2917:
2916:
2912:
2902:
2900:
2896:
2873:
2868:
2867:
2863:
2819:
2818:
2814:
2778:
2777:
2773:
2763:
2761:
2744:
2743:
2739:
2729:
2727:
2718:
2717:
2713:
2703:
2701:
2691:
2690:
2683:
2657:
2656:
2652:
2614:
2613:
2609:
2576:(Suppl 1): S5.
2563:
2562:
2558:
2522:
2521:
2517:
2507:
2505:
2492:
2491:
2480:
2436:
2435:
2431:
2401:
2400:
2396:
2384:
2376:
2374:
2361:
2360:
2353:
2307:
2306:
2302:
2292:
2290:
2285:
2284:
2280:
2270:
2268:
2259:
2258:
2254:
2231:
2230:
2223:
2212:
2197:
2196:
2189:
2179:
2177:
2160:
2159:
2155:
2109:
2108:
2104:
2066:
2065:
2061:
2023:
2022:
2018:
2008:
2006:
1997:
1996:
1977:
1967:
1965:
1956:
1955:
1951:
1940:
1938:
1925:"Mabthera EPAR"
1923:
1922:
1903:
1893:
1891:
1878:
1877:
1856:
1846:
1844:
1843:. 13 March 2021
1835:
1834:
1827:
1817:
1815:
1802:
1801:
1797:
1787:
1785:
1770:
1769:
1765:
1760:Wayback Machine
1751:
1747:
1737:
1735:
1723:
1722:
1718:
1708:
1706:
1693:
1692:
1685:
1675:
1673:
1658:
1657:
1653:
1643:
1641:
1628:"Rixathon EPAR"
1626:
1625:
1621:
1611:
1609:
1596:"Blitzima EPAR"
1594:
1593:
1589:
1579:
1577:
1564:
1563:
1552:
1542:
1540:
1532:
1531:
1520:
1510:
1508:
1495:
1494:
1483:
1478:
1437:
1425:
1413:
1381:
1373:
1371:Tailored-dosing
1334:
1329:
1267:clinical trials
1256:
1228:of CD20+ cells.
1219:B cell receptor
1157:differentiation
1132:
1051:
1019:Devic's disease
958:and autoimmune
908:
860:
847:B-cell leukemia
765:
721:Rituximab is a
625:
623:
620:(what is this?)
617:
607:
605:
595:
589:
583:
577:
571:
532:
508:
500:
480:
460:
440:
424:
404:
363:
352:Bioavailability
344:Pharmacokinetic
338:
322:
258:
214:
207:
188:
181:
28:
23:
22:
15:
12:
11:
5:
7490:
7488:
7480:
7479:
7474:
7469:
7464:
7459:
7454:
7444:
7443:
7439:
7438:
7415:
7414:
7411:
7410:
7409:
7408:
7405:
7394:
7388:
7382:
7381:
7378:
7377:
7374:
7373:
7371:
7370:
7365:
7363:Duvortuxizumab
7360:
7354:
7352:
7348:
7347:
7345:
7344:
7339:
7333:
7331:
7325:
7324:
7322:
7321:
7316:
7311:
7306:
7301:
7296:
7282:
7277:
7272:
7267:
7262:
7257:
7252:
7247:
7242:
7237:
7232:
7227:
7222:
7217:
7212:
7207:
7202:
7197:
7192:
7187:
7182:
7177:
7172:
7167:
7162:
7157:
7152:
7147:
7142:
7137:
7132:
7127:
7122:
7117:
7112:
7107:
7102:
7097:
7092:
7087:
7082:
7077:
7072:
7067:
7062:
7057:
7052:
7047:
7042:
7037:
7032:
7030:Brontictuzumab
7027:
7022:
7017:
7012:
7007:
7002:
6996:
6994:
6988:
6987:
6985:
6984:
6979:
6974:
6969:
6964:
6959:
6954:
6949:
6944:
6939:
6934:
6929:
6924:
6919:
6914:
6909:
6904:
6899:
6894:
6889:
6883:
6881:
6875:
6874:
6872:
6871:
6866:
6861:
6856:
6851:
6846:
6841:
6836:
6831:
6826:
6821:
6816:
6811:
6806:
6801:
6796:
6791:
6786:
6781:
6776:
6771:
6766:
6761:
6756:
6751:
6746:
6741:
6735:
6733:
6729:
6728:
6726:
6725:
6720:
6715:
6710:
6705:
6700:
6695:
6690:
6685:
6680:
6675:
6670:
6665:
6660:
6655:
6650:
6645:
6640:
6635:
6630:
6625:
6620:
6615:
6610:
6605:
6600:
6595:
6590:
6585:
6580:
6575:
6570:
6565:
6560:
6555:
6550:
6545:
6540:
6535:
6530:
6525:
6520:
6515:
6510:
6505:
6500:
6497:+hyaluronidase
6490:
6485:
6480:
6474:
6472:
6465:
6459:
6458:
6452:
6450:
6449:
6442:
6435:
6427:
6418:
6417:
6415:
6414:
6409:
6404:
6399:
6394:
6389:
6384:
6379:
6374:
6369:
6364:
6359:
6354:
6349:
6344:
6339:
6334:
6329:
6324:
6319:
6314:
6309:
6304:
6299:
6298:
6297:
6292:
6287:
6282:
6277:
6267:
6266:
6265:
6260:
6247:
6246:
6245:
6240:
6235:
6230:
6225:
6217:CDK inhibitors
6213:
6212:
6211:
6206:
6201:
6188:
6187:
6186:
6181:
6176:
6164:
6148:
6128:
6116:fusion protein
6111:
6109:
6105:
6104:
6101:
6100:
6098:
6097:
6096:
6095:
6090:
6085:
6080:
6075:
6062:
6061:
6060:
6059:
6054:
6049:
6032:
6031:
6030:
6029:
6024:
6019:
6014:
6001:
6000:
5999:
5998:
5993:
5988:
5983:
5978:
5973:
5968:
5955:
5954:
5948:
5936:
5935:
5934:
5933:
5928:
5923:
5918:
5913:
5908:
5903:
5890:
5888:
5882:
5881:
5879:
5878:
5857:
5856:
5855:(VEGFR, EGFR).
5811:
5810:
5809:
5808:
5803:
5798:
5785:
5784:
5783:
5782:
5777:
5772:
5767:
5762:
5757:
5752:
5747:
5742:
5737:
5732:
5727:
5722:
5709:
5708:
5692:
5686:
5681:
5676:
5671:
5666:
5661:
5656:
5636:
5635:
5634:
5633:
5628:
5623:
5613:HER1/EGFR and
5609:
5608:
5602:
5597:
5592:
5587:
5582:
5577:
5572:
5567:
5562:
5557:
5552:
5547:
5531:
5529:
5520:
5513:
5512:
5509:
5508:
5506:
5505:
5500:
5495:
5490:
5485:
5480:
5475:
5470:
5465:
5460:
5455:
5450:
5445:
5440:
5435:
5430:
5425:
5420:
5415:
5410:
5405:
5400:
5395:
5390:
5385:
5380:
5375:
5370:
5365:
5360:
5355:
5350:
5345:
5340:
5335:
5330:
5325:
5320:
5315:
5310:
5305:
5300:
5295:
5292:+hyaluronidase
5285:
5279:
5277:
5273:
5272:
5270:
5269:
5252:
5251:
5225:
5220:
5215:
5210:
5205:
5200:
5166:
5164:
5154:
5153:
5151:
5150:
5138:
5132:
5120:
5118:
5114:
5113:
5111:
5110:
5104:
5099:
5096:+hyaluronidase
5079:
5073:
5057:
5055:
5046:
5036:
5035:
5021:
5019:
5018:
5011:
5004:
4996:
4990:
4989:
4975:
4974:External links
4972:
4971:
4970:
4960:
4957:
4954:
4953:
4904:
4880:10.1186/bcr276
4853:
4836:"Fc-structure"
4827:
4801:
4766:
4715:
4688:(9): 585–593.
4671:
4614:
4565:
4536:(7): 937–941.
4516:
4481:
4462:(3): 220–224.
4445:
4418:in Colombia".
4409:
4397:. 25 July 2024
4382:
4348:
4333:. 4 May 2020.
4318:
4291:
4265:
4235:
4201:
4175:
4162:Google Patents
4149:
4136:Google Patents
4123:
4074:
4061:Google Patents
4048:
4037:. 24 July 1992
4035:Google Patents
4022:
3988:
3941:
3892:
3871:. 22 June 2017
3849:
3818:
3800:
3784:
3765:(3): 195–197.
3749:
3723:
3682:
3652:
3611:
3572:
3523:
3482:
3438:
3403:
3379:
3344:
3293:
3258:
3207:
3186:(6): 646–650.
3166:
3123:
3082:
3053:
3027:
2986:
2945:
2910:
2861:
2832:(4): 275–280.
2812:
2791:(9): 659–665.
2771:
2760:on 13 May 2009
2737:
2711:
2700:on 29 May 2010
2681:
2650:
2607:
2556:
2515:
2478:
2449:(1): 324–328.
2429:
2410:(5): 385–390.
2394:
2351:
2320:(3): 282–290.
2300:
2278:
2252:
2221:
2210:
2187:
2153:
2102:
2075:(3): 248–253.
2059:
2032:(2): 185–196.
2016:
1975:
1949:
1901:
1854:
1825:
1795:
1763:
1745:
1716:
1683:
1651:
1619:
1587:
1550:
1518:
1480:
1479:
1477:
1474:
1473:
1472:
1453:
1447:
1436:
1433:
1424:
1421:
1412:
1409:
1380:
1377:
1372:
1369:
1338:specialty drug
1333:
1330:
1328:
1325:
1255:
1252:
1248:disulfide bond
1233:
1232:
1229:
1222:
1215:
1208:
1201:
1198:
1191:
1131:
1128:
1127:
1126:
1117:
1111:
1104:
1103:
1102:
1099:
1093:
1080:
1071:
1066:
1064:Cardiac arrest
1061:
1050:
1049:Adverse events
1047:
987:Evans syndrome
907:
904:
859:
856:
851:
850:
835:
829:
816:
814:TNF inhibitors
807:
801:
764:
761:
751:in the US, by
632:
631:
614:
613:
603:
597:
596:
593:
587:
581:
575:
569:
564:
558:
557:
553:
552:
542:
534:
533:
531:
530:
517:
515:
502:
501:
499:
498:
490:
488:
482:
481:
479:
478:
470:
468:
462:
461:
459:
458:
450:
448:
442:
441:
439:
438:
434:
432:
426:
425:
423:
422:
414:
412:
406:
405:
403:
402:
394:
392:
386:
385:
381:
380:
377:
371:
370:
367:
358:
357:
354:
348:
347:
340:
339:
337:
336:
327:
312:
299:
287:
273:
271:
265:
264:
260:
259:
257:
256:
243:
241:
235:
234:
229:
223:
222:
217:
215:administration
209:
208:
206:
205:
203:
193:
191:
183:
182:
180:
179:
161:
159:
153:
152:
145:
139:
138:
131:
121:
120:
117:
111:
110:
107:
101:
100:
96:
95:
90:
84:
83:
69:
63:
62:
61:Whole antibody
59:
53:
52:
46:
45:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
7489:
7478:
7475:
7473:
7470:
7468:
7465:
7463:
7460:
7458:
7455:
7453:
7450:
7449:
7447:
7437:
7427:
7423:
7406:
7404:
7401:
7400:
7398:
7395:
7392:
7389:
7387:
7384:
7383:
7379:
7369:
7366:
7364:
7361:
7359:
7356:
7355:
7353:
7349:
7343:
7340:
7338:
7335:
7334:
7332:
7330:
7326:
7320:
7317:
7315:
7312:
7310:
7307:
7305:
7302:
7300:
7297:
7294:
7290:
7286:
7283:
7281:
7278:
7276:
7273:
7271:
7268:
7266:
7263:
7261:
7258:
7256:
7253:
7251:
7248:
7246:
7245:Rosmantuzumab
7243:
7241:
7238:
7236:
7233:
7231:
7228:
7226:
7223:
7221:
7218:
7216:
7213:
7211:
7208:
7206:
7203:
7201:
7198:
7196:
7193:
7191:
7188:
7186:
7183:
7181:
7178:
7176:
7173:
7171:
7168:
7166:
7163:
7161:
7158:
7156:
7153:
7151:
7148:
7146:
7143:
7141:
7138:
7136:
7133:
7131:
7128:
7126:
7123:
7121:
7118:
7116:
7113:
7111:
7108:
7106:
7103:
7101:
7100:Enoblituzumab
7098:
7096:
7093:
7091:
7088:
7086:
7083:
7081:
7078:
7076:
7073:
7071:
7068:
7066:
7063:
7061:
7058:
7056:
7053:
7051:
7048:
7046:
7043:
7041:
7038:
7036:
7033:
7031:
7028:
7026:
7023:
7021:
7018:
7016:
7013:
7011:
7008:
7006:
7003:
7001:
6998:
6997:
6995:
6993:
6989:
6983:
6980:
6978:
6975:
6973:
6970:
6968:
6965:
6963:
6960:
6958:
6955:
6953:
6950:
6948:
6945:
6943:
6940:
6938:
6935:
6933:
6930:
6928:
6925:
6923:
6920:
6918:
6915:
6913:
6910:
6908:
6905:
6903:
6900:
6898:
6895:
6893:
6890:
6888:
6885:
6884:
6882:
6880:
6876:
6870:
6867:
6865:
6862:
6860:
6857:
6855:
6852:
6850:
6847:
6845:
6842:
6840:
6837:
6835:
6832:
6830:
6827:
6825:
6822:
6820:
6817:
6815:
6812:
6810:
6807:
6805:
6802:
6800:
6797:
6795:
6792:
6790:
6787:
6785:
6782:
6780:
6777:
6775:
6772:
6770:
6767:
6765:
6762:
6760:
6757:
6755:
6752:
6750:
6747:
6745:
6742:
6740:
6737:
6736:
6734:
6730:
6724:
6721:
6719:
6716:
6714:
6711:
6709:
6706:
6704:
6701:
6699:
6696:
6694:
6691:
6689:
6686:
6684:
6681:
6679:
6676:
6674:
6671:
6669:
6666:
6664:
6661:
6659:
6656:
6654:
6653:Pembrolizumab
6651:
6649:
6646:
6644:
6641:
6639:
6636:
6634:
6631:
6629:
6626:
6624:
6621:
6619:
6616:
6614:
6611:
6609:
6606:
6604:
6601:
6599:
6596:
6594:
6591:
6589:
6586:
6584:
6581:
6579:
6576:
6574:
6571:
6569:
6566:
6564:
6561:
6559:
6556:
6554:
6551:
6549:
6546:
6544:
6541:
6539:
6536:
6534:
6531:
6529:
6526:
6524:
6521:
6519:
6516:
6514:
6511:
6509:
6506:
6504:
6501:
6498:
6494:
6491:
6489:
6488:Ascrinvacumab
6486:
6484:
6481:
6479:
6476:
6475:
6473:
6469:
6466:
6464:
6460:
6455:
6448:
6443:
6441:
6436:
6434:
6429:
6428:
6425:
6413:
6410:
6408:
6405:
6403:
6400:
6398:
6395:
6393:
6390:
6388:
6385:
6383:
6380:
6378:
6375:
6373:
6370:
6368:
6365:
6363:
6360:
6358:
6355:
6353:
6350:
6348:
6345:
6343:
6340:
6338:
6335:
6333:
6330:
6328:
6327:Larotrectinib
6325:
6323:
6320:
6318:
6315:
6313:
6310:
6308:
6305:
6303:
6300:
6296:
6293:
6291:
6288:
6286:
6283:
6281:
6278:
6276:
6273:
6272:
6271:
6268:
6264:
6261:
6259:
6256:
6255:
6254:
6252:
6248:
6244:
6241:
6239:
6236:
6234:
6231:
6229:
6226:
6224:
6221:
6220:
6219:
6218:
6214:
6210:
6207:
6205:
6202:
6200:
6197:
6196:
6195:
6193:
6189:
6185:
6182:
6180:
6179:Ridaforolimus
6177:
6175:
6172:
6171:
6170:
6169:
6165:
6162:
6158:
6157:
6153:
6149:
6146:
6142:
6141:
6137:
6133:
6129:
6126:
6122:
6121:
6117:
6113:
6112:
6110:
6106:
6094:
6091:
6089:
6088:Pirtobrutinib
6086:
6084:
6083:Orelabrutinib
6081:
6079:
6076:
6074:
6073:Acalabrutinib
6071:
6070:
6069:
6068:
6064:
6063:
6058:
6055:
6053:
6050:
6048:
6045:
6044:
6043:
6042:
6038:
6034:
6033:
6028:
6025:
6023:
6020:
6018:
6015:
6013:
6010:
6009:
6008:
6007:
6003:
6002:
5997:
5994:
5992:
5989:
5987:
5984:
5982:
5979:
5977:
5974:
5972:
5969:
5967:
5964:
5963:
5962:
5961:
5957:
5956:
5952:
5949:
5947:
5943:
5942:
5938:
5937:
5932:
5929:
5927:
5924:
5922:
5919:
5917:
5914:
5912:
5909:
5907:
5904:
5902:
5899:
5898:
5897:
5896:
5892:
5891:
5889:
5887:
5883:
5876:
5872:
5868:
5865:
5863:
5859:
5858:
5854:
5850:
5849:Selpercatinib
5846:
5845:Repotrectinib
5842:
5838:
5834:
5833:Larotrectinib
5830:
5826:
5822:
5819:
5817:
5813:
5812:
5807:
5804:
5802:
5799:
5797:
5794:
5793:
5792:
5791:
5787:
5786:
5781:
5778:
5776:
5773:
5771:
5768:
5766:
5763:
5761:
5758:
5756:
5753:
5751:
5748:
5746:
5743:
5741:
5738:
5736:
5733:
5731:
5728:
5726:
5723:
5721:
5718:
5717:
5716:
5715:
5711:
5710:
5706:
5702:
5698:
5697:
5693:
5690:
5687:
5685:
5682:
5680:
5677:
5675:
5672:
5670:
5667:
5665:
5662:
5660:
5657:
5655:
5651:
5650:
5646:
5641:
5640:RTK class III
5638:
5637:
5632:
5629:
5627:
5624:
5622:
5619:
5618:
5617:
5616:
5611:
5610:
5606:
5603:
5601:
5598:
5596:
5593:
5591:
5588:
5586:
5583:
5581:
5578:
5576:
5573:
5571:
5568:
5566:
5563:
5561:
5558:
5556:
5553:
5551:
5548:
5546:
5542:
5541:
5536:
5533:
5532:
5530:
5528:
5524:
5521:
5518:
5514:
5504:
5501:
5499:
5496:
5494:
5491:
5489:
5486:
5484:
5481:
5479:
5476:
5474:
5471:
5469:
5466:
5464:
5461:
5459:
5456:
5454:
5451:
5449:
5446:
5444:
5441:
5439:
5436:
5434:
5431:
5429:
5426:
5424:
5423:Pembrolizumab
5421:
5419:
5416:
5414:
5411:
5409:
5406:
5404:
5401:
5399:
5396:
5394:
5391:
5389:
5388:Mogamulizumab
5386:
5384:
5381:
5379:
5376:
5374:
5371:
5369:
5366:
5364:
5361:
5359:
5356:
5354:
5351:
5349:
5346:
5344:
5341:
5339:
5336:
5334:
5331:
5329:
5326:
5324:
5321:
5319:
5316:
5314:
5311:
5309:
5306:
5304:
5301:
5299:
5296:
5293:
5289:
5286:
5284:
5281:
5280:
5278:
5274:
5267:
5263:
5262:
5257:
5254:
5253:
5249:
5245:
5244:
5239:
5235:
5234:
5229:
5226:
5224:
5221:
5219:
5216:
5214:
5211:
5209:
5208:Mosunetuzumab
5206:
5204:
5201:
5199:
5195:
5194:
5189:
5188:Mosunetuzumab
5185:
5181:
5177:
5176:
5171:
5168:
5167:
5165:
5163:
5159:
5155:
5148:
5144:
5143:
5139:
5136:
5133:
5131:
5127:
5126:
5122:
5121:
5119:
5115:
5108:
5105:
5103:
5100:
5097:
5093:
5089:
5085:
5084:
5080:
5077:
5074:
5072:
5068:
5067:
5062:
5059:
5058:
5056:
5054:
5050:
5047:
5044:
5041:
5037:
5032:
5028:
5024:
5017:
5012:
5010:
5005:
5003:
4998:
4997:
4994:
4986:
4982:
4978:
4977:
4973:
4967:
4963:
4962:
4958:
4949:
4945:
4940:
4935:
4931:
4927:
4923:
4919:
4915:
4908:
4905:
4900:
4896:
4891:
4886:
4881:
4876:
4872:
4868:
4864:
4857:
4854:
4841:
4837:
4831:
4828:
4815:
4811:
4805:
4802:
4797:
4793:
4789:
4785:
4781:
4777:
4770:
4767:
4762:
4758:
4753:
4748:
4743:
4738:
4734:
4730:
4726:
4719:
4716:
4711:
4707:
4703:
4699:
4695:
4691:
4687:
4683:
4675:
4672:
4667:
4663:
4659:
4655:
4650:
4645:
4641:
4637:
4633:
4629:
4625:
4618:
4615:
4610:
4606:
4602:
4598:
4593:
4588:
4584:
4580:
4576:
4569:
4566:
4561:
4557:
4553:
4549:
4544:
4539:
4535:
4531:
4527:
4520:
4517:
4512:
4508:
4504:
4500:
4496:
4492:
4485:
4482:
4477:
4473:
4469:
4465:
4461:
4457:
4449:
4446:
4441:
4437:
4433:
4429:
4425:
4421:
4413:
4410:
4396:
4392:
4386:
4383:
4379:
4366:
4362:
4358:
4352:
4349:
4336:
4332:
4328:
4322:
4319:
4306:
4302:
4295:
4292:
4279:
4275:
4269:
4266:
4253:
4251:
4245:
4239:
4236:
4223:
4219:
4217:
4211:
4205:
4202:
4190:
4186:
4179:
4176:
4164:. 31 May 2013
4163:
4159:
4153:
4150:
4137:
4133:
4127:
4124:
4119:
4115:
4110:
4105:
4101:
4097:
4094:(4): 820–37.
4093:
4089:
4085:
4078:
4075:
4062:
4058:
4052:
4049:
4036:
4032:
4026:
4023:
4010:
4006:
4002:
3995:
3993:
3989:
3985:
3984:public domain
3966:
3964:
3958:
3952:
3950:
3948:
3946:
3942:
3938:
3937:public domain
3919:
3917:
3911:
3905:
3903:
3901:
3899:
3897:
3893:
3889:
3888:public domain
3870:
3868:
3862:
3856:
3854:
3850:
3837:
3833:
3829:
3822:
3819:
3814:
3810:
3804:
3801:
3798:2011 page 931
3797:
3793:
3788:
3785:
3780:
3776:
3772:
3768:
3764:
3760:
3753:
3750:
3745:
3741:
3739:
3733:
3727:
3724:
3719:
3715:
3710:
3705:
3701:
3697:
3693:
3686:
3683:
3670:
3666:
3662:
3656:
3653:
3648:
3644:
3639:
3634:
3630:
3626:
3622:
3615:
3612:
3607:
3603:
3599:
3595:
3591:
3587:
3579:
3577:
3573:
3568:
3564:
3559:
3554:
3550:
3546:
3542:
3538:
3534:
3527:
3524:
3519:
3515:
3510:
3505:
3501:
3497:
3493:
3486:
3483:
3478:
3474:
3469:
3464:
3460:
3456:
3452:
3445:
3443:
3439:
3434:
3430:
3426:
3422:
3418:
3414:
3407:
3404:
3396:
3389:
3383:
3380:
3375:
3371:
3367:
3363:
3359:
3355:
3348:
3345:
3340:
3336:
3331:
3326:
3321:
3316:
3312:
3308:
3304:
3297:
3294:
3289:
3285:
3281:
3277:
3273:
3269:
3262:
3259:
3254:
3250:
3245:
3240:
3235:
3230:
3226:
3222:
3218:
3211:
3208:
3203:
3199:
3194:
3189:
3185:
3181:
3177:
3170:
3167:
3162:
3158:
3154:
3150:
3146:
3142:
3138:
3134:
3127:
3124:
3119:
3115:
3110:
3105:
3101:
3097:
3093:
3086:
3083:
3077:
3072:
3068:
3064:
3057:
3054:
3041:
3037:
3031:
3028:
3023:
3019:
3014:
3009:
3005:
3001:
2997:
2990:
2987:
2982:
2978:
2973:
2968:
2964:
2960:
2956:
2949:
2946:
2941:
2937:
2933:
2929:
2925:
2921:
2914:
2911:
2895:
2891:
2887:
2883:
2879:
2872:
2865:
2862:
2857:
2853:
2849:
2845:
2840:
2835:
2831:
2827:
2823:
2816:
2813:
2808:
2804:
2799:
2794:
2790:
2786:
2782:
2775:
2772:
2759:
2755:
2753:
2747:
2741:
2738:
2725:
2721:
2715:
2712:
2699:
2695:
2688:
2686:
2682:
2677:
2673:
2669:
2665:
2661:
2654:
2651:
2646:
2642:
2638:
2634:
2630:
2626:
2623:(1): 89–100.
2622:
2618:
2611:
2608:
2603:
2599:
2594:
2589:
2584:
2579:
2575:
2571:
2567:
2560:
2557:
2552:
2548:
2543:
2538:
2534:
2530:
2526:
2519:
2516:
2503:
2499:
2495:
2489:
2487:
2485:
2483:
2479:
2474:
2470:
2465:
2460:
2456:
2452:
2448:
2444:
2440:
2433:
2430:
2425:
2421:
2417:
2413:
2409:
2405:
2398:
2395:
2391:
2390:public domain
2372:
2368:
2364:
2358:
2356:
2352:
2347:
2343:
2338:
2333:
2328:
2323:
2319:
2315:
2311:
2304:
2301:
2288:
2282:
2279:
2266:
2262:
2256:
2253:
2247:
2242:
2238:
2234:
2228:
2226:
2222:
2217:
2213:
2211:9783034807067
2207:
2203:
2202:
2194:
2192:
2188:
2175:
2171:
2169:
2163:
2157:
2154:
2149:
2145:
2140:
2135:
2130:
2125:
2121:
2117:
2113:
2106:
2103:
2098:
2094:
2090:
2086:
2082:
2078:
2074:
2070:
2063:
2060:
2055:
2051:
2047:
2043:
2039:
2035:
2031:
2027:
2020:
2017:
2004:
2000:
1994:
1992:
1990:
1988:
1986:
1984:
1982:
1980:
1976:
1964:. 3 June 1998
1963:
1959:
1958:"Mabthera PI"
1953:
1950:
1936:
1932:
1931:
1926:
1920:
1918:
1916:
1914:
1912:
1910:
1908:
1906:
1902:
1889:
1885:
1881:
1875:
1873:
1871:
1869:
1867:
1865:
1863:
1861:
1859:
1855:
1842:
1838:
1832:
1830:
1826:
1813:
1809:
1805:
1799:
1796:
1783:
1779:
1778:
1777:Health Canada
1773:
1767:
1764:
1761:
1757:
1754:
1749:
1746:
1734:
1730:
1726:
1720:
1717:
1704:
1700:
1696:
1690:
1688:
1684:
1671:
1667:
1666:
1665:Health Canada
1661:
1655:
1652:
1639:
1635:
1634:
1629:
1623:
1620:
1607:
1603:
1602:
1597:
1591:
1588:
1575:
1571:
1567:
1561:
1559:
1557:
1555:
1551:
1539:
1535:
1529:
1527:
1525:
1523:
1519:
1506:
1502:
1498:
1492:
1490:
1488:
1486:
1482:
1475:
1470:
1466:
1462:
1458:
1454:
1451:
1448:
1445:
1442:
1441:
1440:
1434:
1432:
1430:
1429:intrathecally
1422:
1420:
1418:
1410:
1408:
1406:
1401:
1397:
1392:
1390:
1386:
1378:
1376:
1370:
1368:
1366:
1362:
1358:
1354:
1349:
1346:
1341:
1339:
1331:
1326:
1324:
1320:
1316:
1312:
1310:
1305:
1303:
1300:It is on the
1298:
1296:
1292:
1288:
1284:
1280:
1276:
1272:
1268:
1263:
1261:
1253:
1251:
1249:
1245:
1240:
1238:
1230:
1227:
1223:
1220:
1216:
1213:
1209:
1206:
1203:It increases
1202:
1199:
1196:
1192:
1189:
1185:
1181:
1177:
1176:
1175:
1172:
1168:
1166:
1162:
1158:
1154:
1145:
1136:
1129:
1125:
1121:
1118:
1115:
1112:
1109:
1105:
1100:
1097:
1094:
1091:
1087:
1084:
1083:
1081:
1079:
1075:
1072:
1070:
1067:
1065:
1062:
1060:
1056:
1055:
1054:
1048:
1046:
1044:
1040:
1036:
1032:
1028:
1024:
1020:
1016:
1012:
1008:
1004:
1000:
996:
992:
988:
984:
980:
976:
972:
967:
965:
961:
957:
953:
949:
945:
941:
936:
933:
929:
925:
921:
917:
913:
905:
903:
901:
897:
893:
889:
885:
884:hyaluronidase
881:
877:
873:
869:
865:
858:Blood cancers
857:
855:
848:
844:
840:
836:
834:
830:
828:
824:
820:
817:
815:
811:
808:
805:
802:
799:
796:
795:
794:
792:
787:
785:
781:
777:
773:
770:
762:
760:
758:
754:
750:
746:
742:
737:
735:
731:
727:
724:
719:
717:
713:
709:
705:
700:
696:
694:
690:
686:
682:
678:
674:
670:
666:
662:
658:
654:
651:and types of
650:
646:
642:
638:
628:
621:
615:
604:
602:
598:
565:
563:
559:
554:
550:
546:
543:
541:
539:ECHA InfoCard
535:
527:
523:
522:DTXSID5040910
519:
518:
516:
507:
503:
496:
495:ChEMBL1201576
492:
491:
489:
487:
483:
476:
472:
471:
469:
467:
463:
456:
452:
451:
449:
447:
443:
436:
435:
433:
431:
427:
420:
416:
415:
413:
411:
407:
400:
396:
395:
393:
391:
387:
382:
378:
376:
372:
368:
366:
359:
355:
353:
349:
345:
341:
335: Rx-only
328:
325:
313:
310:
300:
297:
288:
285:
275:
274:
272:
270:
266:
261:
253:
248:
245:
244:
242:
240:
236:
233:
230:
228:
224:
221:
218:
216:
210:
204:
195:
194:
192:
190:
184:
177:
172:
163:
162:
160:
158:
154:
150:
146:
144:
140:
136:
132:
130:
126:
122:
118:
116:
112:
108:
106:
102:
99:Clinical data
97:
94:
91:
89:
85:
81:
77:
73:
70:
68:
64:
60:
58:
54:
51:
47:
43:
38:
30:
19:
7467:Orphan drugs
7260:Sibrotuzumab
7225:Parsatuzumab
7210:Otlertuzumab
7205:Odronextamab
7200:Ocaratuzumab
7195:Obinutuzumab
7170:Lumretuzumab
7125:Flotetuzumab
7120:Ficlatuzumab
7115:Farletuzumab
7110:Etaracizumab
7095:Emibetuzumab
6982:Zolbetuximab
6966:
6957:Margetuximab
6937:Girentuximab
6799:Minretumomab
6764:Blinatumomab
6703:Teprotumumab
6683:Seribantumab
6508:Botensilimab
6493:Atezolizumab
6478:Adecatumumab
6367:Pexidartinib
6352:Odronextamab
6322:Gilteritinib
6302:Cabozantinib
6249:
6215:
6190:
6184:Temsirolimus
6166:
6150:
6132:proapoptotic
6130:
6114:
6093:Zanubrutinib
6065:
6035:
6004:
5981:Lestaurtinib
5960:Janus kinase
5958:
5939:
5893:
5886:Non-receptor
5867:Cabozantinib
5860:
5829:Infigratinib
5814:
5788:
5730:Fruquintinib
5712:
5705:Gilteritinib
5701:Lestaurtinib
5694:
5643:
5612:
5585:Mobocertinib
5550:Aumolertinib
5538:
5503:Tremelimumab
5488:Tislelizumab
5443:Retifanlimab
5318:Blinatumomab
5288:Atezolizumab
5259:
5241:
5231:
5222:
5213:Obinutuzumab
5191:
5173:
5140:
5123:
5081:
5064:
4984:
4921:
4917:
4907:
4873:(2): 86–90.
4870:
4866:
4856:
4844:. Retrieved
4830:
4818:. Retrieved
4814:the original
4804:
4779:
4775:
4769:
4732:
4728:
4718:
4685:
4681:
4674:
4631:
4627:
4617:
4582:
4578:
4568:
4533:
4529:
4519:
4494:
4490:
4484:
4459:
4455:
4448:
4423:
4419:
4412:
4399:. Retrieved
4394:
4385:
4376:
4369:. Retrieved
4360:
4351:
4339:. Retrieved
4330:
4321:
4309:. Retrieved
4294:
4282:. Retrieved
4268:
4256:. Retrieved
4247:
4238:
4226:. Retrieved
4213:
4204:
4192:. Retrieved
4188:
4178:
4166:. Retrieved
4161:
4152:
4140:. Retrieved
4135:
4126:
4091:
4087:
4077:
4065:. Retrieved
4060:
4051:
4039:. Retrieved
4034:
4025:
4013:. Retrieved
4004:
3969:. Retrieved
3960:
3922:. Retrieved
3913:
3873:. Retrieved
3864:
3840:. Retrieved
3831:
3821:
3803:
3795:
3791:
3787:
3762:
3758:
3752:
3744:the original
3735:
3726:
3699:
3695:
3685:
3673:. Retrieved
3669:the original
3664:
3655:
3628:
3624:
3614:
3589:
3585:
3540:
3536:
3526:
3499:
3495:
3485:
3458:
3454:
3416:
3412:
3406:
3395:the original
3382:
3357:
3353:
3347:
3310:
3306:
3296:
3271:
3267:
3261:
3227:(20): 5022.
3224:
3220:
3210:
3183:
3179:
3169:
3136:
3132:
3126:
3099:
3095:
3085:
3067:Pancreapedia
3066:
3056:
3044:. Retrieved
3040:the original
3030:
3003:
2999:
2989:
2962:
2958:
2948:
2923:
2919:
2913:
2901:. Retrieved
2894:the original
2881:
2877:
2864:
2829:
2825:
2815:
2788:
2784:
2774:
2762:. Retrieved
2758:the original
2749:
2740:
2728:. Retrieved
2726:. 9 May 2009
2724:ScienceDaily
2723:
2714:
2702:. Retrieved
2698:the original
2659:
2653:
2620:
2616:
2610:
2573:
2569:
2559:
2532:
2528:
2518:
2506:. Retrieved
2497:
2446:
2442:
2432:
2407:
2403:
2397:
2375:. Retrieved
2366:
2317:
2313:
2303:
2291:. Retrieved
2281:
2269:. Retrieved
2255:
2246:10665/371090
2236:
2200:
2178:. Retrieved
2165:
2156:
2119:
2115:
2105:
2072:
2068:
2062:
2029:
2025:
2019:
2007:. Retrieved
1966:. Retrieved
1961:
1952:
1939:. Retrieved
1928:
1892:. Retrieved
1883:
1845:. Retrieved
1840:
1816:. Retrieved
1807:
1798:
1786:. Retrieved
1775:
1766:
1748:
1736:. Retrieved
1728:
1719:
1707:. Retrieved
1698:
1674:. Retrieved
1663:
1654:
1642:. Retrieved
1631:
1622:
1610:. Retrieved
1599:
1590:
1578:. Retrieved
1569:
1541:. Retrieved
1537:
1509:. Retrieved
1500:
1457:obinutuzumab
1438:
1426:
1414:
1393:
1382:
1374:
1364:
1350:
1342:
1335:
1321:
1317:
1313:
1306:
1299:
1279:chemotherapy
1264:
1257:
1241:
1234:
1173:
1169:
1161:plasma cells
1150:
1098:reactivation
1092:reactivation
1052:
968:
937:
928:methotrexate
924:FDA approved
909:
861:
852:
819:vasculitides
788:
780:plasma cells
766:
763:Medical uses
738:
720:
701:
697:
640:
636:
635:
624:
618:
362:Elimination
269:Legal status
263:Legal status
157:License data
29:
7393:from market
7368:Ontuxizumab
7342:Ertumaxomab
7337:Catumaxomab
7309:Vanucizumab
7289:+deruxtecan
7285:Trastuzumab
7280:Tigatuzumab
7215:Onartuzumab
7190:Nimotuzumab
7180:Milatuzumab
7150:Labetuzumab
7140:Imgatuzumab
7105:Epcoritamab
7090:Emactuzumab
7075:Dalotuzumab
7065:Dacetuzumab
7045:Cirmtuzumab
7020:Bevacizumab
7005:Alemtuzumab
6977:Ublituximab
6927:Ensituximab
6922:Ecromeximab
6917:Dinutuximab
6902:Carotuximab
6892:Bavituximab
6869:Tositumomab
6864:Tenatumomab
6834:Racotumomab
6779:Edrecolomab
6754:Arcitumomab
6723:Zalutumumab
6713:Vantictumab
6688:Sugemalimab
6678:Robatumumab
6673:Rilotumumab
6668:Ramucirumab
6643:Panitumumab
6618:Necitumumab
6608:Mapatumumab
6603:Lucatumumab
6598:Lexatumumab
6588:Istiratumab
6573:Intetumumab
6558:Flanvotumab
6553:Figitumumab
6538:Dusigitumab
6533:Duligotumab
6523:Daratumumab
6518:Conatumumab
6513:Cixutumumab
6503:Balstilimab
6483:Amivantamab
6397:Tebentafusp
6377:Regorafenib
6372:Quizartinib
6362:Pemigatinib
6342:Midostaurin
6317:Erdafitinib
6312:Entrectinib
6295:Parsaclisib
6243:Trilaciclib
6233:Palbociclib
6228:Dalpiciclib
6223:Abemaciclib
6125:Aflibercept
6052:Entrectinib
6022:Selumetinib
6017:Cobimetinib
6012:Binimetinib
5996:Ruxolitinib
5986:Momelotinib
5966:Baricitinib
5864:inhibitors:
5841:Pralsetinib
5837:Pemigatinib
5825:Futibatinib
5821:Entrectinib
5818:inhibitors:
5750:Regorafenib
5654:Avapritinib
5600:Rociletinib
5595:Osimertinib
5560:Dacomitinib
5498:Toripalimab
5483:Teclistamab
5473:Talquetamab
5468:Tafasitamab
5463:Sugemalimab
5458:Serplulimab
5448:Sabatolimab
5438:Ramucirumab
5433:Prolgolimab
5403:Necitumumab
5358:Epcoritamab
5338:Dostarlimab
5328:Daratumumab
5283:Amivantamab
5248:Alemtuzumab
5238:Brentuximab
5228:Tositumomab
5203:Ibritumomab
5184:Elranatamab
5147:Bevacizumab
5135:Edrecolomab
5130:Catumaxomab
5092:Trastuzumab
5076:Panitumumab
4924:(6): 1–13.
4303:. Reuters.
4228:11 November
3661:"Rituximab"
3419:: 275–290.
1999:"Rituximab"
1941:8 September
1461:Fc fragment
1444:ocrelizumab
1423:Intrathecal
1385:hepatitis E
1345:Biosimilars
1244:amino acids
1224:It induces
1186:(ADCC) and
1124:perforation
1096:Hepatitis B
1082:Infections
1041:(OMS), and
896:fludarabine
774:present on
704:hepatitis B
612: g·mol
545:100.224.382
399:174722-31-7
384:Identifiers
220:Intravenous
143:MedlinePlus
115:Biosimilars
105:Trade names
7446:Categories
7314:Veltuzumab
7293:+emtansine
7265:Simtuzumab
7230:Pertuzumab
7160:Lintuzumab
7135:Glofitamab
7085:Elotuzumab
7070:Demcizumab
7010:Axatilimab
7000:Abituzumab
6972:Siltuximab
6947:Isatuximab
6887:Amatuximab
6859:Pintumomab
6829:Pemtumomab
6824:Oregovomab
6759:Bectumomab
6739:Abagovomab
6693:Tarextumab
6663:Radretumab
6658:Pritumumab
6648:Patritumab
6638:Olaratumab
6633:Ofatumumab
6623:Nesvacumab
6613:Narnatumab
6583:Iratumumab
6578:Ipilimumab
6548:Enoticumab
6528:Drozitumab
6456:for tumors
6412:Venetoclax
6407:Vandetanib
6382:Ripretinib
6347:Nintedanib
6332:Lenvatinib
6307:Capmatinib
6290:Idelalisib
6280:Copanlisib
6253:inhibitors
6238:Ribociclib
6209:Vismodegib
6194:inhibitors
6174:Everolimus
6140:prohibitin
6057:Lorlatinib
6047:Crizotinib
6027:Trametinib
5991:Pacritinib
5976:Filgotinib
5971:Fedratinib
5875:Crizotinib
5871:Capmatinib
5853:Vandetanib
5801:Brigatinib
5780:Vandetanib
5740:Nintedanib
5735:Lenvatinib
5674:Ripretinib
5605:Vandetanib
5580:Lazertinib
5555:Brigatinib
5478:Tarlatamab
5413:Olaratumab
5373:Isatuximab
5368:Ipilimumab
5348:Elotuzumab
5343:Durvalumab
5323:Cemiplimab
5313:Bermekimab
5303:Axatilimab
5218:Ofatumumab
5198:Glofitamab
5180:Glofitamab
5088:Pertuzumab
4846:3 December
4820:3 December
4735:(2): 325.
4497:(6): 430.
4426:: 98–104.
4311:3 November
4015:26 October
3592:: 106684.
3313:: 731643.
3096:Pediatrics
3046:19 October
2884:(2): 107.
2508:2 February
2377:4 December
2180:2 February
2009:8 December
1894:2 February
1738:22 October
1709:2 February
1476:References
1450:ofatumumab
1237:stem cells
1195:cell cycle
1139:rituximab.
1076:, causing
1003:pemphigoid
920:refractory
793:to treat:
687:-positive
601:Molar mass
455:4F4X42SYQ6
430:ChemSpider
390:CAS Number
227:Drug class
7403:Phase III
7391:Withdrawn
7185:Naxitamab
7175:Matuzumab
6992:Humanized
6967:Rituximab
6932:Futuximab
6907:Cetuximab
6844:Solitomab
6804:Mitumomab
6794:Lilotomab
6774:Detumomab
6718:Votumumab
6708:Tovetumab
6628:Nivolumab
6593:Icrucumab
6563:Ganitumab
6402:Tepotinib
6392:Sunitinib
6387:Sorafenib
6357:Pazopanib
6337:Masitinib
6285:Duvelisib
6275:Alpelisib
6263:Sotorasib
6258:Adagrasib
6204:Sonidegib
6199:Glasdegib
6145:Adipotide
6078:Ibrutinib
5951:Dasatinib
5946:Bosutinib
5931:Radotinib
5926:Ponatinib
5921:Nilotinib
5911:Dasatinib
5906:Bosutinib
5901:Asciminib
5869:(VEGFR),
5827:(FGFR2),
5806:Ceritinib
5796:Alectinib
5775:Toceranib
5770:Tivozanib
5765:Sunitinib
5760:Sorafenib
5755:Semaxanib
5745:Pazopanib
5725:Cediranib
5689:Toceranib
5684:Sunitinib
5679:Sorafenib
5669:Pazopanib
5664:Masitinib
5631:Tucatinib
5626:Neratinib
5621:Lapatinib
5590:Olmutinib
5570:Gefitinib
5565:Erlotinib
5540:HER1/EGFR
5408:Nivolumab
5398:Naxitamab
5223:Rituximab
5071:Cetuximab
5066:HER1/EGFR
4666:248695128
4609:235710318
2293:27 August
2122:(1): 28.
2116:Pathogens
1699:Drugs.com
1644:7 January
1332:Economics
1226:apoptosis
1114:Pulmonary
999:pemphigus
944:off-label
932:TNF-alpha
872:lymphomas
868:leukemias
841:(DLBCL),
791:indicated
749:Genentech
716:pregnancy
637:Rituximab
375:Excretion
364:half-life
356:100% (IV)
213:Routes of
187:Pregnancy
176:Rituximab
135:Monograph
129:Drugs.com
34:Rituximab
7436:Medicine
6879:Chimeric
6789:Igovomab
6192:hedgehog
6154:against
6152:exotoxin
6118:against
6067:Bruton's
5916:Imatinib
5839:(FGFR),
5835:(NTRK),
5720:Axitinib
5659:Axitinib
5615:HER2/neu
5575:Icotinib
5545:Afatinib
5519:("-nib")
5298:Avelumab
5170:lymphoid
5162:lymphoma
5158:Leukemia
5083:HER2/neu
5045:("-mab")
4948:25578468
4899:11250751
4840:Archived
4796:25355180
4761:38256459
4752:10816159
4710:91186383
4702:30934066
4658:35544139
4601:34212816
4560:21878513
4552:17981914
4511:19293085
4476:26915311
4440:34922060
4371:23 April
4365:Archived
4341:30 March
4335:Archived
4305:Archived
4284:29 April
4278:Archived
4222:Archived
4118:24866199
4009:Archived
3836:Archived
3813:Archived
3675:14 March
3647:16705086
3606:34438120
3567:14532151
3518:23613524
3477:30030508
3455:Leukemia
3433:26443686
3374:12826649
3339:34527001
3288:22422012
3253:36291806
3202:25901938
3161:39750214
3153:25809420
3118:15601813
3022:18779415
2981:17065638
2940:14601692
2903:18 April
2856:42218074
2848:15795920
2807:26293834
2764:29 April
2676:24310855
2645:36762194
2637:27756172
2602:21624184
2551:15201414
2502:Archived
2498:DailyMed
2473:29222274
2424:21183282
2371:Archived
2346:28584371
2265:Archived
2235:(2023).
2216:Archived
2174:Archived
2148:29518976
2097:35805200
2089:28306595
2054:19504332
2046:28164324
2003:Archived
1935:Archived
1888:Archived
1884:DailyMed
1847:26 March
1818:26 March
1812:Archived
1788:25 March
1782:Archived
1756:Archived
1703:Archived
1670:Archived
1638:Archived
1606:Archived
1580:26 March
1574:Archived
1570:DailyMed
1543:26 March
1538:DailyMed
1511:26 March
1505:Archived
1501:DailyMed
1379:Research
1365:Ituxredi
1116:toxicity
1110:patients
1108:lymphoma
1090:JC virus
866:such as
821:such as
723:chimeric
627:(verify)
410:DrugBank
239:ATC code
189:category
171:DailyMed
72:Chimeric
5895:bcr-abl
5256:myeloid
4939:4340844
4649:9096596
4401:27 July
4194:27 July
4168:27 July
4142:27 July
4109:4171018
4067:27 July
4041:27 July
3779:9652253
3718:9310469
3558:1766758
3330:8435594
3244:9599435
3221:Cancers
2593:3123966
2464:6142570
2337:5448263
2271:30 June
2139:5874754
1355:of the
1311:(CLL).
1254:History
1057:Severe
995:bullous
985:(ITP),
981:(TTP),
960:anemias
849:(B-AL).
776:B cells
772:antigen
769:surface
734:B cells
641:Rituxan
562:Formula
419:DB00073
326:Rx-only
323:WARNING
294::
255:)
249: (
247:L01FA01
202: C
173::
149:a607038
18:Truxima
7422:Portal
7386:WHO-EM
5142:VEGF-A
4946:
4936:
4897:
4890:138676
4887:
4794:
4759:
4749:
4708:
4700:
4664:
4656:
4646:
4607:
4599:
4558:
4550:
4509:
4474:
4438:
4258:5 July
4116:
4106:
3971:5 July
3924:5 July
3875:5 July
3842:9 June
3777:
3716:
3645:
3604:
3565:
3555:
3516:
3475:
3431:
3372:
3337:
3327:
3286:
3251:
3241:
3200:
3159:
3151:
3116:
3020:
2979:
2938:
2854:
2846:
2805:
2730:5 July
2704:22 May
2674:
2643:
2635:
2600:
2590:
2549:
2471:
2461:
2422:
2344:
2334:
2208:
2146:
2136:
2095:
2087:
2052:
2044:
1968:5 July
1676:29 May
1612:1 July
1205:MHC II
1190:(CDC).
940:safety
745:Biogen
653:cancer
486:ChEMBL
475:D02994
320:
307:
296:℞-only
282:
169:
88:Target
67:Source
6732:Mouse
6471:Human
6463:Tumor
6136:ANXA2
6108:Other
6006:MAP2K
5877:(ALK)
5862:c-MET
5714:VEGFR
5649:PDGFR
5645:C-kit
5276:Other
5125:EpCAM
4706:S2CID
4662:S2CID
4605:S2CID
4556:S2CID
4252:(FDA)
4248:U.S.
4218:(FDA)
4214:U.S.
3965:(FDA)
3961:U.S.
3918:(FDA)
3914:U.S.
3869:(FDA)
3865:U.S.
3740:(FDA)
3736:U.S.
3696:Blood
3625:Blood
3496:Blood
3398:(PDF)
3391:(PDF)
3157:S2CID
2897:(PDF)
2874:(PDF)
2852:S2CID
2754:(FDA)
2750:U.S.
2641:S2CID
2170:(FDA)
2166:U.S.
2093:S2CID
2050:S2CID
1841:(emc)
1808:(emc)
1389:acute
806:(CLL)
800:(NHL)
753:Roche
80:human
76:mouse
6251:KRAS
6156:IL-2
6138:and
6120:VEGF
6037:EML4
5696:FLT3
5647:and
5535:ErbB
5261:CD33
5243:CD52
5233:CD30
5193:CD20
5061:ErbB
4944:PMID
4895:PMID
4848:2007
4822:2007
4792:PMID
4757:PMID
4698:PMID
4654:PMID
4597:PMID
4548:PMID
4507:PMID
4472:PMID
4436:PMID
4403:2024
4373:2021
4343:2024
4313:2018
4286:2017
4260:2024
4230:2019
4196:2024
4170:2024
4144:2024
4114:PMID
4088:mAbs
4069:2024
4043:2024
4017:2015
4005:Time
3973:2024
3926:2024
3877:2024
3844:2016
3775:PMID
3714:PMID
3677:2023
3643:PMID
3602:PMID
3563:PMID
3514:PMID
3473:PMID
3429:PMID
3370:PMID
3335:PMID
3284:PMID
3249:PMID
3198:PMID
3149:PMID
3114:PMID
3048:2011
3018:PMID
2977:PMID
2936:PMID
2905:2007
2844:PMID
2803:PMID
2766:2013
2732:2024
2706:2009
2672:PMID
2633:PMID
2598:PMID
2547:PMID
2510:2020
2469:PMID
2447:2017
2420:PMID
2379:2021
2342:PMID
2295:2024
2273:2021
2206:ISBN
2182:2020
2144:PMID
2085:PMID
2042:PMID
2011:2016
1970:2024
1943:2021
1896:2020
1849:2021
1820:2021
1790:2024
1740:2023
1711:2020
1678:2022
1646:2024
1614:2024
1582:2021
1545:2021
1513:2021
1212:CD23
1178:The
1153:CD20
1122:and
1017:and
898:and
870:and
825:and
782:and
747:and
730:CD20
683:and
588:1987
582:1688
576:9874
570:6416
466:KEGG
446:UNII
437:none
346:data
125:AHFS
93:CD20
57:Type
6041:ALK
5941:Src
5816:RET
5790:ALK
5240:),
5230:),
5190:),
5175:CD3
5031:L01
4934:PMC
4926:doi
4885:PMC
4875:doi
4784:doi
4747:PMC
4737:doi
4690:doi
4686:170
4644:PMC
4636:doi
4587:doi
4538:doi
4499:doi
4495:150
4464:doi
4460:172
4428:doi
4104:PMC
4096:doi
3767:doi
3704:doi
3633:doi
3629:108
3594:doi
3590:111
3553:PMC
3545:doi
3504:doi
3500:121
3463:doi
3421:doi
3362:doi
3358:348
3325:PMC
3315:doi
3276:doi
3239:PMC
3229:doi
3188:doi
3184:151
3141:doi
3104:doi
3100:115
3071:doi
3008:doi
2967:doi
2963:355
2928:doi
2886:doi
2834:doi
2793:doi
2664:doi
2625:doi
2588:PMC
2578:doi
2537:doi
2533:350
2459:PMC
2451:doi
2412:doi
2332:PMC
2322:doi
2241:hdl
2134:PMC
2124:doi
2077:doi
2034:doi
1733:FDA
1029:),
993:),
610:.04
608:860
606:143
511:EPA
309:POM
252:WHO
7448::
7399::
7291:/
5873:,
5843:,
5831:,
5703:,
5642::
5537::
5258::
5186:,
5182:,
5172::
5090:,
5063::
5040:CI
5025:/
4983:.
4942:.
4932:.
4922:57
4920:.
4916:.
4893:.
4883:.
4869:.
4865:.
4838:.
4790:.
4780:15
4778:.
4755:.
4745:.
4733:13
4731:.
4727:.
4704:.
4696:.
4684:.
4660:.
4652:.
4642:.
4630:.
4626:.
4603:.
4595:.
4583:28
4581:.
4577:.
4554:.
4546:.
4534:67
4532:.
4528:.
4505:.
4493:.
4470:.
4458:.
4434:.
4424:28
4422:.
4393:.
4375:.
4359:.
4329:.
4246:.
4212:.
4187:.
4160:.
4134:.
4112:.
4102:.
4090:.
4086:.
4059:.
4033:.
4007:.
4003:.
3991:^
3959:.
3944:^
3912:.
3895:^
3863:.
3852:^
3834:.
3830:.
3773:.
3761:.
3734:.
3712:.
3700:90
3698:.
3694:.
3663:.
3641:.
3627:.
3623:.
3600:.
3588:.
3575:^
3561:.
3551:.
3541:62
3539:.
3535:.
3512:.
3498:.
3494:.
3471:.
3459:32
3457:.
3453:.
3441:^
3427:.
3417:97
3415:.
3368:.
3356:.
3333:.
3323:.
3311:12
3309:.
3305:.
3282:.
3272:64
3270:.
3247:.
3237:.
3225:14
3223:.
3219:.
3196:.
3182:.
3178:.
3155:.
3147:.
3137:67
3135:.
3112:.
3098:.
3094:.
3069:.
3065:.
3016:.
3004:65
3002:.
2998:.
2975:.
2961:.
2957:.
2934:.
2924:78
2922:.
2880:.
2850:.
2842:.
2830:78
2828:.
2824:.
2801:.
2789:26
2787:.
2783:.
2748:.
2722:.
2684:^
2670:.
2639:.
2631:.
2621:16
2619:.
2596:.
2586:.
2574:13
2572:.
2568:.
2545:.
2531:.
2527:.
2496:.
2481:^
2467:.
2457:.
2445:.
2441:.
2418:.
2408:37
2406:.
2365:.
2354:^
2340:.
2330:.
2318:62
2316:.
2312:.
2224:^
2214:.
2190:^
2164:.
2142:.
2132:.
2118:.
2114:.
2091:.
2083:.
2073:29
2071:.
2048:.
2040:.
2030:56
2028:.
1978:^
1960:.
1927:.
1904:^
1882:.
1857:^
1839:.
1828:^
1806:.
1774:.
1731:.
1727:.
1697:.
1686:^
1662:.
1630:.
1598:.
1572:.
1568:.
1553:^
1536:.
1521:^
1503:.
1499:.
1484:^
1407:.
1304:.
1297:.
1239:.
1180:Fc
1165:Ca
1037:,
1033:,
1025:,
1013:,
1009:,
1001:,
977:,
973:,
954:,
950:,
890:,
710:,
679:,
675:,
671:,
667:,
659:,
594:44
331:EU
316:US
303:UK
291:CA
284:S4
278:AU
198:AU
166:US
7424::
7295:)
7287:(
6499:)
6495:(
6446:e
6439:t
6432:v
6163:)
6159:(
6147:)
6143:(
6127:)
6123:(
6039:-
5953:)
5944:(
5699:(
5691:)
5652:(
5607:)
5543:(
5294:)
5290:(
5268:)
5264:(
5250:)
5246:(
5236:(
5196:(
5178:(
5160:/
5149:)
5145:(
5137:)
5128:(
5109:)
5098:)
5094:(
5086:(
5078:)
5069:(
5033:)
5029:(
5015:e
5008:t
5001:v
4950:.
4928::
4901:.
4877::
4871:3
4850:.
4824:.
4798:.
4786::
4763:.
4739::
4712:.
4692::
4668:.
4638::
4632:5
4611:.
4589::
4562:.
4540::
4513:.
4501::
4478:.
4466::
4442:.
4430::
4405:.
4345:.
4315:.
4288:.
4262:.
4232:.
4198:.
4172:.
4146:.
4120:.
4098::
4092:6
4071:.
4045:.
4019:.
3986:.
3975:.
3939:.
3928:.
3890:.
3879:.
3846:.
3781:.
3769::
3763:6
3720:.
3706::
3679:.
3649:.
3635::
3608:.
3596::
3569:.
3547::
3520:.
3506::
3479:.
3465::
3435:.
3423::
3376:.
3364::
3341:.
3317::
3290:.
3278::
3255:.
3231::
3204:.
3190::
3163:.
3143::
3120:.
3106::
3079:.
3073::
3050:.
3024:.
3010::
2983:.
2969::
2942:.
2930::
2907:.
2888::
2882:4
2858:.
2836::
2809:.
2795::
2768:.
2734:.
2708:.
2678:.
2666::
2647:.
2627::
2604:.
2580::
2553:.
2539::
2512:.
2475:.
2453::
2426:.
2414::
2392:.
2381:.
2348:.
2324::
2275:.
2243::
2184:.
2150:.
2126::
2120:7
2099:.
2079::
2056:.
2036::
2013:.
1972:.
1945:.
1898:.
1851:.
1822:.
1792:.
1742:.
1713:.
1680:.
1648:.
1616:.
1584:.
1547:.
1515:.
1221:.
1214:.
1197:.
1021:(
591:S
585:O
579:N
573:H
567:C
513:)
509:(
333::
318::
305::
280::
200::
127:/
82:)
78:/
74:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
